



US008626255B2

(12) **United States Patent**
Al-Ali et al.

(10) **Patent No.:** **US 8,626,255 B2**
(45) **Date of Patent:** ***Jan. 7, 2014**

(54) **NONINVASIVE MULTI-PARAMETER
PATIENT MONITOR**

(56) **References Cited**

U.S. PATENT DOCUMENTS

(75) Inventors: **Ammar Al-Ali**, Tustin, CA (US); **Joe E. Kiani**, Laguna Niguel, CA (US); **Mohamed K. Diab**, Mission Viejo, CA (US); **Greg A. Olsen**, Irvine, CA (US); **Roger C. Wu**, Irvine, CA (US); **Rick Fishel**, Orange, CA (US)

3,910,701 A 10/1975 Henderson et al.
4,051,522 A 9/1977 Healy
4,085,378 A 4/1978 Ryan

(Continued)

FOREIGN PATENT DOCUMENTS

(73) Assignee: **Cercacor Laboratories, Inc.**, Irvine, CA (US)

DE 3328862 A1 2/1985
EP 0104771 B1 4/1984

(Continued)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 49 days.

This patent is subject to a terminal disclaimer.

OTHER PUBLICATIONS

Burritt, M.; Current Analytical Approaches to Measuring Blood Analytes; vol. 36; No. 8(B); 1990.

(Continued)

(21) Appl. No.: **13/477,979**

(22) Filed: **May 22, 2012**

(65) **Prior Publication Data**

US 2012/0232359 A1 Sep. 13, 2012

Related U.S. Application Data

(63) Continuation of application No. 11/367,033, filed on Mar. 1, 2006, now Pat. No. 8,190,223.

(60) Provisional application No. 60/657,596, filed on Mar. 1, 2005, provisional application No. 60/657,281, filed on Mar. 1, 2005, provisional application No. 60/657,268, filed on Mar. 1, 2005, provisional application No. 60/657,759, filed on Mar. 1, 2005.

(51) **Int. Cl.**
A61B 5/1455 (2006.01)

(52) **U.S. Cl.**
USPC **600/310; 600/323; 600/324**

(58) **Field of Classification Search**
USPC **600/309-344**
See application file for complete search history.

Primary Examiner — Eric Winakur


Assistant Examiner — Marjan Fardanesh

(74) *Attorney, Agent, or Firm* — Knobbe Martens Olson & Bear LLP

(57) **ABSTRACT**

Embodiments of the present disclosure include a handheld multi-parameter patient monitor capable of determining multiple physiological parameters from the output of a light sensitive detector capable of detecting light attenuated by body tissue. For example, in an embodiment, the monitor is capable of advantageously and accurately displaying one or more of pulse rate, plethysmograph data, perfusion quality, signal confidence, and values of blood constituents in body tissue, including for example, arterial carbon monoxide saturation ("HbCO"), methemoglobin saturation ("HbMet"), total hemoglobin ("Hbt"), arterial oxygen saturation ("SpO₂"), fractional arterial oxygen saturation ("SpaO₂"), or the like. In an embodiment, the monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display real estate.

15 Claims, 18 Drawing Sheets



(56)

References Cited

U.S. PATENT DOCUMENTS

4,267,844	A	5/1981	Yamanishi	5,490,505	A	2/1996	Diab et al.
4,531,527	A	7/1985	Reinhold, Jr. et al.	5,494,043	A	2/1996	O'Sullivan et al.
4,623,248	A	11/1986	Sperinde	5,503,148	A	4/1996	Pologe
4,653,498	A	3/1987	New	5,533,511	A	7/1996	Kaspari et al.
4,655,225	A	4/1987	Dahne et al.	5,534,851	A	7/1996	Russek
4,685,464	A	8/1987	Goldberger et al.	5,542,421	A	8/1996	Erdman
4,745,398	A	5/1988	Abel	5,549,111	A	8/1996	Wright et al.
4,765,340	A	8/1988	Sakai	5,561,275	A	10/1996	Savage et al.
4,800,495	A	1/1989	Smith	5,562,002	A	10/1996	Lalin
4,802,486	A	2/1989	Goodman	5,575,284	A	11/1996	Athan et al.
4,805,623	A	2/1989	Jobsis	5,588,435	A	12/1996	Weng et al.
4,854,328	A	8/1989	Pollack	5,590,649	A	1/1997	Caro et al.
4,863,265	A	9/1989	Flower et al.	5,602,924	A	2/1997	Durand et al.
4,870,588	A	9/1989	Merhav	5,608,820	A	3/1997	Vaidyanathan
4,911,167	A	3/1990	Corenman et al.	5,610,996	A	3/1997	Eller
4,934,372	A	6/1990	Corenman et al.	5,632,272	A	5/1997	Diab et al.
4,938,218	A	7/1990	Goodman et al.	5,638,816	A	6/1997	Kiani-Azarbayjany et al.
4,942,877	A	7/1990	Sakai	5,638,818	A	6/1997	Diab et al.
4,955,379	A	9/1990	Hall	5,645,440	A	7/1997	Tobler et al.
4,960,128	A	10/1990	Gordon et al.	5,652,566	A	7/1997	Lambert
4,964,408	A	10/1990	Hink et al.	5,685,299	A	11/1997	Diab et al.
4,965,840	A	10/1990	Subbarao	5,719,589	A	2/1998	Norman et al.
5,003,252	A	3/1991	Nystrom	5,720,284	A	2/1998	Aoyagi et al.
5,025,791	A	6/1991	Niwa	5,720,293	A	2/1998	Quinn
RE33,643	E	7/1991	Isaacson	D393,830	S	4/1998	Tobler et al.
5,028,787	A	7/1991	Rosenthal et al.	5,743,262	A	4/1998	Lepper, Jr. et al.
5,041,187	A	8/1991	Hink et al.	5,758,644	A	6/1998	Diab et al.
5,069,213	A	12/1991	Polczynski	5,760,910	A	6/1998	Lepper, Jr. et al.
5,077,476	A	12/1991	Rosenthal	5,769,785	A	6/1998	Diab et al.
5,137,023	A	8/1992	Mendelson et al.	5,782,237	A	7/1998	Casciani
5,163,438	A	11/1992	Gordon et al.	5,782,757	A	7/1998	Diab et al.
5,170,791	A	12/1992	Boos et al.	5,785,659	A	7/1998	Caro et al.
5,188,108	A	2/1993	Secker	5,791,347	A	8/1998	Flaherty et al.
5,189,609	A	2/1993	Tivig et al.	5,810,734	A	9/1998	Caro et al.
5,190,038	A	3/1993	Polson	5,820,267	A	10/1998	Bryars
5,193,124	A	3/1993	Subbarao	5,823,950	A	10/1998	Diab et al.
5,218,962	A	6/1993	Mannheimer	5,830,131	A	11/1998	Caro et al.
5,226,053	A	7/1993	Cho et al.	5,833,618	A	11/1998	Caro et al.
5,226,417	A	7/1993	Swedlow	5,842,979	A	12/1998	Jarman
5,246,002	A	9/1993	Prosser	5,853,364	A	12/1998	Baker, Jr. et al.
5,247,931	A	9/1993	Norwood	5,860,919	A	1/1999	Kiani-Azarbayjany et al.
5,259,381	A	11/1993	Cheung	5,865,736	A	2/1999	Baker, Jr. et al.
5,270,942	A	12/1993	Reed	5,890,929	A	4/1999	Mills et al.
5,307,284	A	4/1994	Brunfeldt	5,891,022	A	4/1999	Pologe
5,319,355	A	6/1994	Russek	5,891,023	A	4/1999	Lynn
5,331,394	A	7/1994	Shalon et al.	5,904,654	A	5/1999	Wohlmann et al.
5,337,744	A	8/1994	Branigan	5,919,134	A	7/1999	Diab
5,337,745	A	8/1994	Benaron	5,921,921	A	7/1999	Potratz et al.
5,341,805	A	8/1994	Stavridi et al.	5,934,925	A	8/1999	Tobler et al.
5,345,510	A	9/1994	Singhi	5,940,182	A	8/1999	Lepper, Jr. et al.
5,353,356	A	10/1994	Waugh et al.	5,950,139	A	9/1999	Korycan
5,355,882	A	10/1994	Ukawa et al.	5,987,343	A	11/1999	Kinast
5,357,965	A	10/1994	Hall et al.	5,995,855	A	11/1999	Kiani et al.
5,368,224	A	11/1994	Richardson	5,997,343	A	12/1999	Mills et al.
D353,195	S	12/1994	Savage et al.	6,002,952	A	12/1999	Diab et al.
D353,196	S	12/1994	Savage et al.	6,011,986	A	1/2000	Diab et al.
5,377,676	A	1/1995	Vari et al.	6,027,452	A	2/2000	Flaherty et al.
5,384,451	A	1/1995	Smith et al.	6,036,642	A	3/2000	Diab et al.
5,398,003	A	3/1995	Heyl et al.	6,045,509	A	4/2000	Caro et al.
5,404,003	A	4/1995	Smith	6,047,203	A	4/2000	Sackner et al.
5,406,952	A	4/1995	Barnes	6,064,910	A	5/2000	Andersson et al.
D359,546	S	6/1995	Savage et al.	6,067,462	A	5/2000	Diab et al.
5,421,329	A	6/1995	Casciani	6,081,735	A	6/2000	Diab et al.
5,431,170	A	7/1995	Mathews	6,083,172	A	7/2000	Baker, Jr. et al.
D361,840	S	8/1995	Savage et al.	6,088,607	A	7/2000	Diab et al.
5,438,983	A	8/1995	Flacone	6,110,522	A	8/2000	Lepper, Jr. et al.
5,442,940	A	8/1995	Secker et al.	6,119,026	A	9/2000	McNulty et al.
D362,063	S	9/1995	Savage et al.	6,122,535	A	9/2000	Kaestle et al.
5,448,991	A	9/1995	Polson	6,124,597	A	9/2000	Shehada et al.
5,452,717	A	9/1995	Branigan et al.	6,128,521	A	10/2000	Marro et al.
D363,120	S	10/1995	Savage et al.	6,129,675	A	10/2000	Jay
5,456,252	A	10/1995	Vari et al.	6,135,952	A	10/2000	Coetzee
5,479,934	A	1/1996	Imran	6,144,868	A	11/2000	Parker
5,481,620	A	1/1996	Vaidyanathan	6,149,588	A	11/2000	Noda et al.
5,482,036	A	1/1996	Diab et al.	6,151,516	A	11/2000	Kiani-Azarbayjany et al.
				6,152,754	A	11/2000	Gerhardt et al.
				6,157,850	A	12/2000	Diab et al.
				6,165,005	A	12/2000	Mills et al.
				6,174,283	B1	1/2001	Nevo et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,184,521 B1	2/2001	Coffin, IV et al.	6,725,075 B2	4/2004	Al-Ali
6,188,407 B1	2/2001	Smith et al.	6,728,560 B2	4/2004	Kollias et al.
6,192,261 B1	2/2001	Gratton et al.	6,735,459 B2	5/2004	Parker
6,206,830 B1	3/2001	Diab et al.	6,743,172 B1	6/2004	Blike
6,229,856 B1	5/2001	Diab et al.	6,745,060 B2	6/2004	Diab et al.
6,232,609 B1	5/2001	Snyder et al.	6,760,607 B2	7/2004	Al-Ali
6,236,872 B1	5/2001	Diab et al.	6,770,028 B1	8/2004	Ali et al.
6,241,683 B1	6/2001	Macklem et al.	6,771,994 B2	8/2004	Kiani et al.
6,253,097 B1	6/2001	Aronow et al.	6,792,300 B1	9/2004	Diab et al.
6,256,523 B1	7/2001	Diab et al.	6,800,373 B2	10/2004	Corczyca
6,262,698 B1	7/2001	Blum	6,813,511 B2	11/2004	Diab et al.
6,263,222 B1	7/2001	Diab et al.	6,816,741 B2	11/2004	Diab
6,278,522 B1	8/2001	Lepper, Jr. et al.	6,822,564 B2	11/2004	Al-Ali
6,280,213 B1	8/2001	Tobler et al.	6,826,419 B2	11/2004	Diab et al.
6,285,895 B1	9/2001	Ristolainen et al.	6,829,501 B2	12/2004	Nielsen et al.
6,285,896 B1	9/2001	Tobler et al.	6,830,711 B2	12/2004	Mills et al.
6,301,493 B1	10/2001	Marro et al.	6,850,787 B2	2/2005	Weber et al.
6,317,627 B1	11/2001	Ennen et al.	6,850,788 B2	2/2005	Al-Ali
6,321,100 B1	11/2001	Parker	6,852,083 B2	2/2005	Caro et al.
6,325,761 B1	12/2001	Jay	6,861,639 B2	3/2005	Al-Ali
6,334,065 B1	12/2001	Al-Ali et al.	6,861,641 B1	3/2005	Adams
6,343,224 B1	1/2002	Parker	6,898,452 B2	5/2005	Al-Ali et al.
6,349,228 B1	2/2002	Kiani et al.	6,920,345 B2	7/2005	Al-Ali et al.
6,360,113 B1	3/2002	Dettling	6,931,268 B1	8/2005	Kiani-Azarbayjany et al.
6,360,114 B1	3/2002	Diab et al.	6,934,570 B2	8/2005	Kiani et al.
6,368,283 B1	4/2002	Xu et al.	6,939,305 B2	9/2005	Flaherty et al.
6,371,921 B1	4/2002	Caro et al.	6,943,348 B1	9/2005	Coffin, IV
6,377,829 B1	4/2002	Al-Ali	6,950,687 B2	9/2005	Al-Ali
6,388,240 B2	5/2002	Schulz et al.	6,956,572 B2	10/2005	Zaleski
6,397,091 B2	5/2002	Diab et al.	6,961,598 B2	11/2005	Diab
6,430,437 B1	8/2002	Marro	6,970,792 B1	11/2005	Diab
6,430,525 B1	8/2002	Weber et al.	6,979,812 B2	12/2005	Al-Ali
6,455,340 B1	9/2002	Chua et al.	6,985,764 B2	1/2006	Mason et al.
6,463,311 B1	10/2002	Diab	6,993,371 B2	1/2006	Kiani et al.
6,466,824 B1	10/2002	Struble	6,996,427 B2	2/2006	Ali et al.
6,470,199 B1	10/2002	Kopotic et al.	6,999,904 B2	2/2006	Weber et al.
6,501,975 B2	12/2002	Diab et al.	7,003,338 B2	2/2006	Weber et al.
6,505,059 B1	1/2003	Kollias et al.	7,003,339 B2	2/2006	Diab et al.
6,505,061 B2	1/2003	Larson	7,015,451 B2	3/2006	Dalke et al.
6,515,273 B2	2/2003	Al-Ali	7,024,233 B2	4/2006	Ali et al.
6,519,486 B1	2/2003	Edgar, Jr. et al.	7,027,849 B2	4/2006	Al-Ali
6,519,487 B1	2/2003	Parker	7,030,749 B2	4/2006	Al-Ali
6,525,386 B1	2/2003	Mills et al.	7,039,449 B2	5/2006	Al-Ali
6,526,300 B1	2/2003	Kiani et al.	7,041,060 B2	5/2006	Flaherty et al.
6,541,756 B2	4/2003	Schulz et al.	7,044,918 B2	5/2006	Diab
6,542,764 B1	4/2003	Al-Ali et al.	7,067,893 B2	6/2006	Mills et al.
6,545,652 B1	4/2003	Tsuji	7,096,052 B2	8/2006	Mason et al.
6,580,086 B1	6/2003	Schulz et al.	7,096,054 B2	8/2006	Abdul-Hafiz et al.
6,584,336 B1	6/2003	Ali et al.	7,132,641 B2	11/2006	Schulz et al.
6,595,316 B2	7/2003	Cybulski et al.	7,142,901 B2	11/2006	Kiani et al.
6,597,932 B2	7/2003	Tian et al.	7,149,561 B2	12/2006	Diab
6,597,933 B2	7/2003	Kiani et al.	7,186,966 B2	3/2007	Al-Ali
6,606,511 B1	8/2003	Ali et al.	7,190,261 B2	3/2007	Al-Ali
6,632,181 B2	10/2003	Flaherty et al.	7,215,984 B2	5/2007	Diab
6,639,668 B1	10/2003	Trepagnier	7,215,986 B2	5/2007	Diab
6,640,116 B2	10/2003	Diab	7,221,971 B2	5/2007	Diab
6,643,530 B2	11/2003	Diab et al.	7,225,006 B2	5/2007	Al-Ali et al.
6,650,917 B2	11/2003	Diab et al.	7,225,007 B2	5/2007	Al-Ali
6,654,624 B2	11/2003	Diab et al.	RE39,672 E	6/2007	Shehada et al.
6,658,276 B2	12/2003	Kiani et al.	7,239,905 B2	7/2007	Kiani-Azarbayjany et al.
6,661,161 B1	12/2003	Lanzo et al.	7,245,953 B1	7/2007	Parker
6,671,531 B2	12/2003	Al-Ali et al.	7,254,429 B2	8/2007	Schurman et al.
6,678,543 B2	1/2004	Diab et al.	7,254,431 B2	8/2007	Al-Ali et al.
6,684,090 B2	1/2004	Ali et al.	7,254,433 B2	8/2007	Diab et al.
6,684,091 B2	1/2004	Parker	7,254,434 B2	8/2007	Schulz et al.
6,690,466 B2	2/2004	Miller et al.	7,272,425 B2	9/2007	Al-Ali
6,697,656 B1	2/2004	Al-Ali	7,274,955 B2	9/2007	Kiani et al.
6,697,657 B1	2/2004	Shehada et al.	D554,263 S	10/2007	Al-Ali
6,697,658 B2	2/2004	Al-Ali	7,280,858 B2	10/2007	Al-Ali et al.
RE38,476 E	3/2004	Diab et al.	7,289,835 B2	10/2007	Mansfield et al.
6,699,194 B1	3/2004	Diab et al.	7,292,883 B2	11/2007	De Felice et al.
6,714,804 B2	3/2004	Al-Ali et al.	7,295,866 B2	11/2007	Al-Ali
RE38,492 E	4/2004	Diab et al.	7,299,080 B2	11/2007	Acosta et al.
6,721,582 B2	4/2004	Trepagnier et al.	7,328,053 B1	2/2008	Diab et al.
6,721,585 B1	4/2004	Parker	7,332,784 B2	2/2008	Mills et al.
			7,340,287 B2	3/2008	Mason et al.
			7,341,559 B2	3/2008	Schulz et al.
			7,343,186 B2	3/2008	Lamego et al.
			D566,282 S	4/2008	Al-Ali et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,355,512 B1	4/2008	Al-Ali	7,962,188 B2	6/2011	Kiani et al.
7,356,365 B2	4/2008	Schurman	7,962,190 B1	6/2011	Diab et al.
7,371,981 B2	5/2008	Abdul-Hafiz	7,976,472 B2	7/2011	Kiani
7,373,193 B2	5/2008	Al-Ali et al.	7,988,637 B2	8/2011	Diab
7,373,194 B2	5/2008	Weber et al.	7,990,382 B2	8/2011	Kiani
7,376,453 B1	5/2008	Diab et al.	7,991,446 B2	8/2011	Ali et al.
7,377,794 B2	5/2008	Al-Ali et al.	8,000,761 B2	8/2011	Al-Ali
7,377,899 B2	5/2008	Weber et al.	8,008,088 B2	8/2011	Bellott et al.
7,383,070 B2	6/2008	Diab et al.	RE42,753 E	9/2011	Kiani-Azarbayjany et al.
7,415,297 B2	8/2008	Al-Ali et al.	8,019,400 B2	9/2011	Diab et al.
7,428,432 B2	9/2008	Ali et al.	8,028,701 B2	10/2011	Al-Ali et al.
7,438,683 B2	10/2008	Al-Ali et al.	8,029,765 B2	10/2011	Bellott et al.
7,440,786 B2	10/2008	Hockersmith et al.	8,036,728 B2	10/2011	Diab et al.
7,440,787 B2	10/2008	Diab	8,046,040 B2	10/2011	Ali et al.
7,454,240 B2	11/2008	Diab et al.	8,046,041 B2	10/2011	Diab et al.
7,467,002 B2	12/2008	Weber et al.	8,046,042 B2	10/2011	Diab et al.
7,469,157 B2	12/2008	Diab et al.	8,048,040 B2	11/2011	Kiani
7,471,969 B2	12/2008	Diab et al.	8,050,728 B2	11/2011	Al-Ali et al.
7,471,971 B2	12/2008	Diab et al.	RE43,169 E	2/2012	Parker
7,483,729 B2	1/2009	Al-Ali et al.	8,118,620 B2	2/2012	Al-Ali et al.
7,483,730 B2	1/2009	Diab et al.	8,126,528 B2	2/2012	Diab et al.
7,489,958 B2	2/2009	Diab et al.	8,128,572 B2	3/2012	Diab et al.
7,496,391 B2	2/2009	Diab et al.	8,130,105 B2	3/2012	Al-Ali et al.
7,496,393 B2	2/2009	Diab et al.	8,145,287 B2	3/2012	Diab et al.
D587,657 S	3/2009	Al-Ali et al.	8,150,487 B2	4/2012	Diab et al.
7,499,741 B2	3/2009	Diab et al.	8,175,672 B2	5/2012	Parker
7,499,835 B2	3/2009	Weber et al.	8,180,420 B2	5/2012	Diab et al.
7,500,950 B2	3/2009	Al-Ali et al.	8,182,443 B1	5/2012	Kiani
7,509,154 B2	3/2009	Diab et al.	8,185,180 B2	5/2012	Diab et al.
7,509,494 B2	3/2009	Al-Ali	8,190,223 B2	5/2012	Al-Ali et al.
7,510,849 B2	3/2009	Schurman et al.	8,190,227 B2	5/2012	Diab et al.
7,526,328 B2	4/2009	Diab et al.	8,203,438 B2	6/2012	Kiani et al.
7,530,942 B1	5/2009	Diab	8,203,704 B2	6/2012	Merritt et al.
7,530,949 B2	5/2009	Al Ali et al.	8,224,411 B2	7/2012	Al-Ali et al.
7,530,955 B2	5/2009	Diab et al.	8,228,181 B2	7/2012	Al-Ali
7,563,110 B2	7/2009	Al-Ali et al.	8,229,533 B2	7/2012	Diab et al.
7,596,398 B2	9/2009	Al-Ali et al.	8,233,955 B2	7/2012	Al-Ali et al.
7,618,375 B2	11/2009	Flaherty	8,244,325 B2	8/2012	Al-Ali et al.
D606,659 S	12/2009	Kiani et al.	8,255,026 B1	8/2012	Al-Ali
7,647,083 B2	1/2010	Al-Ali et al.	8,255,027 B2	8/2012	Al-Ali et al.
D609,193 S	2/2010	Al-Ali et al.	8,255,028 B2	8/2012	Al-Ali et al.
D614,305 S	4/2010	Al-Ali et al.	8,260,577 B2	9/2012	Weber et al.
RE41,317 E	5/2010	Parker	8,265,723 B1	9/2012	McHale et al.
7,729,733 B2	6/2010	Al-Ali et al.	8,274,360 B2	9/2012	Sampath et al.
7,734,320 B2	6/2010	Al-Ali	8,301,217 B2	10/2012	Al-Ali et al.
7,735,729 B2	6/2010	Rowe et al.	8,310,336 B2	11/2012	Muhsin et al.
7,761,127 B2	7/2010	Al-Ali et al.	8,315,683 B2	11/2012	Al-Ali et al.
7,761,128 B2	7/2010	Al-Ali et al.	RE43,860 E	12/2012	Parker
7,764,982 B2	7/2010	Dalke et al.	8,337,403 B2	12/2012	Al-Ali et al.
D621,516 S	8/2010	Kiani et al.	8,346,330 B2	1/2013	Lamego
7,791,155 B2	9/2010	Diab	8,353,842 B2	1/2013	Al-Ali et al.
7,801,581 B2	9/2010	Diab	8,355,766 B2	1/2013	MacNeish, III et al.
7,822,452 B2	10/2010	Schurman et al.	8,359,080 B2	1/2013	Diab et al.
RE41,912 E	11/2010	Parker	8,364,223 B2	1/2013	Al-Ali et al.
7,844,313 B2	11/2010	Kiani et al.	8,364,226 B2	1/2013	Diab et al.
7,844,314 B2	11/2010	Al-Ali	8,374,665 B2	2/2013	Lamego
7,844,315 B2	11/2010	Al-Ali	8,385,995 B2	2/2013	Al-Ali et al.
7,865,222 B2	1/2011	Weber et al.	8,385,996 B2	2/2013	Smith et al.
7,873,497 B2	1/2011	Weber et al.	8,388,353 B2	3/2013	Kiani et al.
7,880,606 B2	2/2011	Al-Ali	8,399,822 B2	3/2013	Al-Ali
7,880,626 B2	2/2011	Al-Ali et al.	8,401,602 B2	3/2013	Kiani
7,891,355 B2	2/2011	Al-Ali et al.	8,405,608 B2	3/2013	Al-Ali et al.
7,894,868 B2	2/2011	Al-Ali et al.	8,414,499 B2	4/2013	Al-Ali et al.
7,899,507 B2	3/2011	Al-Ali et al.	8,418,524 B2	4/2013	Al-Ali
7,899,518 B2	3/2011	Trepagnier et al.	8,423,106 B2	4/2013	Lamego et al.
7,904,132 B2	3/2011	Weber et al.	2001/0045532 A1	11/2001	Schulz et al.
7,909,772 B2	3/2011	Popov et al.	2002/0021269 A1	2/2002	Rast
7,910,875 B2	3/2011	Al-Ali	2002/0026107 A1	2/2002	Kiani et al.
7,919,713 B2	4/2011	Al-Ali et al.	2002/0035318 A1	3/2002	Mannheimer et al.
7,937,128 B2	5/2011	Al-Ali	2002/0038078 A1	3/2002	Ito
7,937,129 B2	5/2011	Mason et al.	2002/0038081 A1	3/2002	Fein et al.
7,937,130 B2	5/2011	Diab et al.	2002/0059047 A1	5/2002	Haaland
7,941,199 B2	5/2011	Kiani	2002/0082488 A1	6/2002	Al-Ali
7,951,086 B2	5/2011	Flaherty et al.	2002/0095078 A1	7/2002	Mannheimer et al.
7,957,780 B2	6/2011	Lamego et al.	2002/0111748 A1	8/2002	Kobayashi et al.
			2002/0115919 A1	8/2002	Al-Ali
			2002/0154665 A1	10/2002	Funabashi et al.
			2002/0156353 A1	10/2002	Larson
			2002/0159002 A1	10/2002	Chang

(56)

References Cited

U.S. PATENT DOCUMENTS

2002/0161291 A1 10/2002 Kianl
 2002/0165440 A1 11/2002 Mason et al.
 2003/0000522 A1 1/2003 Lynn
 2003/0018241 A1 1/2003 Mannheimer
 2003/0045784 A1 3/2003 Palatnik et al.
 2003/0045785 A1 3/2003 Diab et al.
 2003/0049232 A1 3/2003 Page et al.
 2003/0073890 A1 4/2003 Hanna
 2003/0109775 A1 6/2003 O'Neil et al.
 2003/0116769 A1 6/2003 Song et al.
 2003/0117296 A1 6/2003 Seely
 2003/0120160 A1 6/2003 Yarita
 2003/0120164 A1 6/2003 Nielsen
 2003/0135099 A1 7/2003 Al-Ali
 2003/0139657 A1 7/2003 Solenberger
 2003/0160257 A1 8/2003 Bader et al.
 2003/0195402 A1 10/2003 Fein et al.
 2004/0006261 A1 1/2004 Swedlow et al.
 2004/0033618 A1 2/2004 Haass et al.
 2004/0034898 A1 2/2004 Bruegl
 2004/0059209 A1 3/2004 Al-Ali et al.
 2004/0064259 A1 4/2004 Haaland et al.
 2004/0081621 A1 4/2004 Arndt et al.
 2004/0092805 A1 5/2004 Yarita
 2004/0133087 A1 7/2004 Ali et al.
 2004/0138538 A1 7/2004 Stetson
 2004/0138540 A1 7/2004 Baker, Jr. et al.
 2004/0147822 A1 7/2004 Al-Ali et al.
 2004/0147823 A1 7/2004 Kiani et al.
 2004/0158132 A1 8/2004 Zaleski
 2004/0158134 A1 8/2004 Diab et al.
 2004/0158135 A1 8/2004 Baker, Jr. et al.
 2004/0162472 A1 8/2004 Berson et al.
 2004/0167382 A1 8/2004 Gardner et al.
 2004/0176670 A1 9/2004 Takamura et al.
 2004/0181134 A1 9/2004 Baker, Jr. et al.
 2004/0199063 A1 10/2004 O'Neil et al.
 2004/0204639 A1 10/2004 Casciani et al.
 2004/0204868 A1 10/2004 Maynard et al.
 2004/0229391 A1 11/2004 Ohya et al.
 2004/0262046 A1 12/2004 Simon et al.
 2004/0267103 A1 12/2004 Li et al.
 2004/0267140 A1 12/2004 Ito et al.
 2005/0043902 A1 2/2005 Haaland et al.
 2005/0049469 A1 3/2005 Aoyagi et al.
 2005/0054908 A1 3/2005 Blank et al.
 2005/0070773 A1 3/2005 Chin et al.
 2005/0070775 A1 3/2005 Chin et al.
 2005/0075546 A1 4/2005 Samsoundar et al.
 2005/0085704 A1 4/2005 Schulz et al.
 2005/0085735 A1 4/2005 Baker, Jr. et al.
 2005/0124871 A1 6/2005 Baker, Jr. et al.
 2005/0143634 A1 6/2005 Baker, Jr. et al.
 2005/0143943 A1 6/2005 Brown
 2005/0148834 A1 7/2005 Hull et al.
 2005/0184895 A1 8/2005 Petersen et al.
 2005/0187447 A1 8/2005 Chew et al.
 2005/0187448 A1 8/2005 Petersen et al.
 2005/0187449 A1 8/2005 Chew et al.
 2005/0187450 A1 8/2005 Chew et al.
 2005/0187452 A1 8/2005 Petersen et al.
 2005/0187453 A1 8/2005 Petersen et al.
 2005/0197549 A1 9/2005 Baker, Jr.
 2005/0197579 A1 9/2005 Baker, Jr.
 2005/0197793 A1 9/2005 Baker, Jr.
 2005/0203357 A1 9/2005 Debreczeny et al.
 2005/0209515 A1 9/2005 Hockersmith et al.
 2005/0228253 A1 10/2005 Debreczeny
 2005/0250997 A1 11/2005 Takeda et al.
 2006/0030764 A1 2/2006 Porges et al.
 2006/0210120 A1 9/2006 Rowe et al.
 2006/0211922 A1 9/2006 Al-Ali et al.
 2006/0211923 A1 9/2006 Al-Ali et al.
 2006/0211924 A1 9/2006 Smith et al.
 2006/0211925 A1 9/2006 Lamego et al.

2006/0211932 A1 9/2006 Al-Ali et al.
 2006/0226992 A1 10/2006 Al-Ali et al.
 2006/0229509 A1 10/2006 Al-Ali et al.
 2006/0238358 A1 10/2006 Al-Ali et al.
 2006/0241358 A1 10/2006 Al-Ali et al.
 2006/0241363 A1 10/2006 Al-Ali et al.
 2011/0009719 A1 1/2011 Al-Ali et al.
 2011/0237914 A1 9/2011 Lamego

FOREIGN PATENT DOCUMENTS

EP 0352923 A1 1/1990
 EP 41 92 23 3/1991
 EP 0 569 670 2/1993
 EP 0569670 11/1993
 EP 645117 A 3/1995
 EP 0659384 6/1995
 EP 0 675 541 10/1995
 EP 1 895 892 5/2010
 EP 2 305 104 4/2011
 JP 61-28172 2/1986
 JP 63-275327 11/1988
 JP 64-500495 2/1989
 JP 2-145457 12/1990
 JP 05-207993 8/1993
 JP 6-505903 7/1994
 JP 6-237013 8/1994
 JP 7-281618 10/1995
 JP 07-325546 12/1995
 JP 9-192120 7/1997
 JP 10-216112 8/1998
 JP 10-509352 9/1998
 JP 10-269344 10/1998
 JP 10-269344 A 10/1998
 JP 10-295676 11/1998
 JP 10-305026 11/1998
 JP 11-163412 6/1999
 JP 11-164826 6/1999
 JP 11-506834 6/1999
 JP 11-183377 7/1999
 JP 2000-116625 4/2000
 JP 2002-516689 6/2002
 JP 2002-228579 8/2002
 JP 2002-525151 8/2002
 JP 2002-315739 10/2002
 JP 2003-507718 2/2003
 JP 2003-084108 3/2003
 JP 2003-521985 7/2003
 JP 2004-070179 3/2004
 JP 2004-226277 8/2004
 JP 2004-296736 10/2004
 JP 2004-532526 10/2004
 JP 2004-327760 11/2004
 JP 2005-501589 1/2005
 JP 2005-253478 9/2005
 JP 4879913 12/2011
 WO WO 84/03032 8/1984
 WO WO 88/01150 2/1988
 WO WO 88/02020 2/1988
 WO WO 92/11803 7/1992
 WO WO 92/15955 9/1992
 WO WO 92/16142 10/1992
 WO WO 92/20273 11/1992
 WO WO 95/16387 6/1995
 WO WO 95/21567 8/1995
 WO WO 96/13208 5/1996
 WO WO 97/01985 1/1997
 WO WO 98/43071 10/1998
 WO WO 98-43071 10/1998
 WO WO 00/18290 4/2000
 WO WO 00/42911 A1 7/2000
 WO WO 01/13790 3/2001
 WO WO 01/30414 5/2001
 WO WO 01/058347 8/2001
 WO WO 02/17780 3/2002
 WO WO 02/26123 4/2002
 WO WO 02/089664 11/2002
 WO WO 03/020129 3/2003
 WO WO 03-068060 8/2003

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO	WO 03/068060	8/2003
WO	WO 2004/034898	4/2004
WO	WO 2005/011488	2/2005
WO	WO 2006/094168	9/2006

OTHER PUBLICATIONS

European Examination Report dated Apr. 1, 2010, re EP App. No. 08 744 412.1-2319.

European Examination Report dated Mar. 18, 2011, re EP App. No. 08 744 412.1-2319.

European Examination Report dated Sep. 2, 2010, re EP App. No. 08 744 412.1-2319.

European Extended Search Report re EPO App. No. 10162402.1, SR dated Aug. 9, 2010.

Hall J., "Near-Infrared Spectrophotometry: A New Dimension in Clinical Chemistry", vol. 38; No. 9; 1992.

International Search Report dated Jan. 11, 2007, for PCT/US2006/007516, filed Mar. 1, 2006.

Japanese First Office Action (Notice of Reasons for Rejection), re JP App. No. 2007-558247, dated Jun. 28, 2011.

Japanese Office Action (Notice of Allowance), re JP App. No. 2007-558247, dated Oct. 24, 2011.

Japanese Office Action (Notice of Reasons for Rejection) re JP App. No. 2007-558246, dated Jun. 28, 2011.

Japanese Office Action (Notice of Reasons for Rejection), re JP App. No. 2007-558238, dated Jun. 28, 2011.

Japanese Office Action re JP Application No. 2007-558249, dated Jul. 13, 2011.

Japanese Office Action re JP Application No. 2007-558249, dated Nov. 8, 2011.

Japanese Office Action re JP Application No. JP 2007-558208, dated Aug. 23, 2011.

Japanese Office Action re JP Application No. JP 2007-558248, dated Nov. 8, 2011.

Japanese Office Action re JP Application No. 2007-558209, dated Oct. 25, 2011.

Japanese Office Action re JP Application No. 2007-558245, dated Oct. 25, 2011.

Japanese Office Action, re JP Application No. 2007-558237, dated Aug. 1, 2011.

Kuenstner, et al., J. Todd; Measurement of Hemoglobin in Unlysed Blood by Near-Infrared Spectroscopy; vol. 48; No. 4, 1994.

Manzke, et al., B., Multi Wavelength Pulse OXimetry in the Measurement of Hemoglobin Fractions; vol. 2676, date unknown.

Naumenko, E. K.; Choice of Wavelengths for Stable Determination of Concentrations of Hemoglobin Derivatives from Absorption Spectra of Erythrocytes; vol. 63; No. 1; pp. 60-66 Jan.-Feb. 1996; Original article submitted Nov. 3, 1994.

Patent Cooperation Treaty (PCT) International Search Report; PCT-US 2006-007389; Date of Mailing Jul. 17, 2006; pp. 1-9.

PCT International Search Report; PCT/US2006/007506; Date of Mailing Jul. 17, 2006; pp. 1-10.

PCT Search Report of International Application No. PCT/US2008/058327, Mailing Date of Jun. 30, 2009, in 12 pages.

Schmitt, E., "Measurement of Blood Hematocrit by Dual-wavelength Near-IR Photoplethysmography", Physiological Monitoring and Early Detection Diagnostic Methods, Proc. SPIE vol. 1641, p. 150-161, May 1992.

Schmitt, J.; Simple Photon Diffusion Analysis of the Effects of Multiple Scattering on Pulse Oximetry; Mar. 14, 1991; revised Aug. 30, 1991.

Schnapp, et al., L. M.; Pulse Oximetry. Uses and Abuses.; Chest 1990; 98; 1244-1250001 10.1378/Chest.98.5.1244.

Appendix for Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Patent No. 5,632,272, U.S. Patent No. 6,263,222, U.S. Patent No. 7,215,984, and U.S. Patent No. 6,699,194, *Masimo Corporation v. Philips Electronics*

North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012.

Blitt, Casey D., *Monitoring in Anesthesia and Critical Care Medicine*, (2d ed. 1990).

Boualem Boashash, *Estimating and Interpreting the Instantaneous Frequency of a Signal-Part I: Fundamentals*, Proceedings of the IEEE, vol. 80, No. 4 (Apr. 1992).

Boualem Boashash, *Note on the Use of the Wigner Distribution for Time-Frequency Signal Analysis*, IEEE Transactions on Acoustics, Speech, and Signal Processing, vol. 36, No. 9 (Sep. 1988).

Business Wire, "Mallinckrodt Announces the Nellcor N-395 Pulse Oximeter With Oxismart XL and SatSeconds," Oct. 7, 1999.

Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,632,272, Doc. 554, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 551, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 508, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 21, 2012.

Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 7,215,984, Doc. 561, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Declaration of Mohammed K. Diab in Support of Masimo's Oppositions to Defendants' Motions for Summary Judgment of Invalidity and Noninfringement of U.S. Patent Nos. 5,632,272 and 7,215,984, Doc. 563, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted).

Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 7,215,984, vol. 1, Doc. 556, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 5,632,272, Doc. 553, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 548, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Declaration of Perry D. Oldham in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 7,215,984, vol. 2, Doc. 558, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Declaration of Perry D. Oldham in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 550, *Masimo Corporation v. Philips*

(56)

References Cited

OTHER PUBLICATIONS

Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted).

Defendants' Answer and Philips Electronics North America Corp.'s Counterclaims to Masimo's First Amended Complaint, Doc. 11, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Nov. 7, 2011. Defendants' Answer and Philips Electronics North America Corp.'s Counterclaims to Masimo's Second Amended Complaint, Doc. 43, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated May 11, 2012. Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,632,272, Doc. 402, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.

Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 410, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.

Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 406, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.

Defendants' Objections to Magistrate Judge Thyne's Report and Recommendation Regarding Claim Construction, Doc. 218, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2011.

Edward Bedrosian, *The Analytic Signal Representation of Modulating Waveforms* (1962).

Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Patent No. 5,632,272, U.S. Patent No. 6,263,222, U.S. Patent No. 7,215,984, and U.S. Patent No. 6,699,194, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012.

Hanzo et al., "A Portable Multimedia Communicator Scheme", *Multimedia Technologies and Future Applications: Proceedings of the IEEE International Symposium* (1994).

Maciej Niedzwiecki et al. "Smoothing of Discontinuous Signals: The Competitive Approach," *IEEE Transactions on Signal Processing*, vol. 43, No. 1, Jan. 1995, pp. 1-13.

Masimo Corporation's Answering Brief in Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,632,272, Doc. 552, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Masimo Corporation's Answering Brief in Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 7,215,984, Doc. 555, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted).

Masimo Corporation's Answering Brief in Opposition to Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 549, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted).

Masimo Corporation's Objections to the Report and Recommendation Regarding Claim Construction, Doc. 219, *Masimo Corporation v. Philips Electronics North America Corporation and Philips*

Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 8, 2011.

Masimo Corporation's Response to Defendants' Objections to the Report and Recommendation Regarding Claim Construction, Doc. 232, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 24, 2011. Masimo's Answer to Philips' Counterclaims to Masimo's Second Amended Complaint, Doc. 358, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Jun. 4, 2012.

Masimo's Answer to Philips' Counterclaims, Doc. 28, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Dec. 30, 2011.

Memorandum Order Adopting Report and Recommendation Regarding Claim Construction, Doc. 319, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Jan. 17, 2011.

Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,632,272, Doc. 444, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted).

Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,699,194, Doc. 445, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted).

Philip Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 7,215,984, Doc. 394, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.

Philip's Opening Brief in Support of Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 7,215,984, Doc. 442, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted).

Philips' Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 413, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012.

Philips' Response to Masimo Corporation's Objections to the Report and Recommendation Regarding Claim Construction, Doc. 230, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 24, 2011.

Reply Brief in Support of Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Patent No. 5,632,272, Doc. 614, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012 (Redacted).

Reply Brief in Support of Defendants' Motion for Summary Judgment of invalidity and Noninfringement of U.S. Patent No. 7,216,984, Doc. 609, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012. (Redacted).

Reply Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Patent No. 6,263,222, Doc. 613, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012 (Redacted).

(56)

References Cited

OTHER PUBLICATIONS

Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012. (Redacted).

Report and Recommendation Regarding Claim Construction, Doc. 210, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Feb. 18, 2011. Revised Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Patent No. 5,632,272, U.S. Patent No. 6,263,222, U.S. Patent No. 7,215,984, and U.S. Patent No. 6,699,194, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012.

Rusch, "Master's Thesis," Graduate School University of South Florida, Tampa, Florida (Dec. 1994).

Scharf, "Optimization of Portable Pulse Oximetry Through Fourier Analysis".

Scharf, "Pulse Oximetry Through Spectral Analysis".

Second Amended Complaint for Patent Infringement, Doc. 42, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Apr. 25, 2012.

Steven W. Smith, *The Scientist and Engineer's Guide to Digital Signal Processing*, § 8 (1st ed. 1997).

Supplemental Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Patent No. 5,632,272, U.S. Patent No. 6,263,222, U.S. Patent No. 7,215,984, and U.S. Patent No. 6,699,194, *Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GmbH*, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 18, 2012.

U.S. Appl. No. 90/012,551, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 6,970,792, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,553, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,024,233, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,403, filed Jul. 23, 2012, requesting ex parte reexamination of Patent No. 6,263,222, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,409, filed Aug. 17, 2012, requesting ex parte reexamination of Patent No. 6,699,194, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,463, filed Sep. 5, 2012, requesting ex parte reexamination of Patent No. 7,215,984, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,532, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,499,835, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,534, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,962,188, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,538, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,377,899, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,541, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,899,507, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,542, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 8,180,420, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,543, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 6,850,787, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,546, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,438,683, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,548, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,880,606, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,557, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 8,150,487, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,561, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 8,019,400, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,562, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 6,463,311, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,566, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 7,530,955, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,567, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 6,684,090, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,568, filed Sep. 14, 2012, requesting ex parte reexamination of Patent No. 8,128,572, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,699, filed Oct. 4, 2012, requesting ex parte reexamination of Patent No. 6,002,952, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 90/012,555, filed Sep. 13, 2012, requesting ex parte reexamination of Patent No. 7,440,787, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302.

U.S. Appl. No. 95/002,183, filed Sep. 12, 2012, requesting inter partes reexamination of Patent No. 7,530,955, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.913 and 35 U.S.C. § 311.

V. Ya. Volkov, "Enhancing the Reliability and Accuracy of Pulse Oximetry with a Built-In Expert System," *Biomedical Engineering*, vol. 27, No. 3 (May-Jun. 1993) (translated from Russian).

V. Ya. Volkov, "Principles and Algorithms for Determining Blood Oxygenation Level by Pulse Oximetry," *Biomedical Engineering*, vol. 27, No. 1 (Jan.-Feb. 1993) (translated from Russian).

Wukitsch, et al., "Knowing Your Monitoring Equipment," *Journal of Clinical Monitoring*, vol. 4, No. 4 (Oct. 1998).

Burritt, Mary F.; Current Analytical Approaches to Measuring Blood Analyses; vol. 36; No. 8(B); 1990.

Hall, et al., Jeffrey W.; Near-Infrared Spectrophotometry: A New Dimension in Clinical Chemistry; vol. 38; No. 9; 1992.

International Search Report for PCT/US2006/007516, mailed on Jan. 11, 2007, in 4 pages.

(56)

References Cited

OTHER PUBLICATIONS

Japanese First Office Action (Notice of Reasons for Rejection), re JP App. No. 2007-558207, dated Jun. 28, 2011.
PCT Search Report of International Application No. PCT/US2008/058327, Mailing Date of Aug. 12, 2008, in 6 pages.

Schmitt, Joseph M.; Simple Photon Diffusion Analysis of the Effects of Multiple Scattering on Pulse Oximetry; Mar. 14, 1991; revised Aug. 30, 1991.

Schmitt, Joseph M.; Zhou, Guan-Xiong; Miller, Justin, *Measurement of Blood Hematocrit by Dual-Wavelength Near-IR Photoplethysmography*, Published May 1992, Proc. Spie vol. 1641, p. 150-161, Physiological Monitoring and Early Detection Diagnostic Methods, Thomas S. Mang; Ed. (Spie Homepage), in 12 Pages.




FIG. 1





FIG. 2







FIG. 4






FIG. 6




FIG. 7






FIG. 8








FIG. 11A




FIG. 11B




FIG. 11C




FIG. 11D




FIG. 11E




FIG. 11F




FIG. 11G




FIG. 11H

1

NONINVASIVE MULTI-PARAMETER PATIENT MONITOR

PRIORITY CLAIM TO RELATED PROVISIONAL APPLICATIONS

The present application is a continuation of U.S. patent application Ser. No. 11/367,033, filed Mar. 1, 2006, which claims priority benefit under 35 U.S.C. §119(e) to U.S. Provisional Patent Application Ser. No. 60/657,596, filed Mar. 1, 2005, entitled "Multiple Wavelength Sensor;" No. 60/657,281, filed Mar. 1, 2005, entitled "Physiological Parameter Confidence Measure;" No. 60/657,268, filed Mar. 1, 2005, entitled "Configurable Physiological Measurement System;" and No. 60/657,759, filed Mar. 1, 2005, entitled "Noninvasive Multi-Parameter Patient Monitor." The present application incorporates the foregoing disclosures herein by reference.

INCORPORATION BY REFERENCE OF RELATED UTILITY APPLICATIONS

The present application is related to the following copending U.S. utility applications:

App. Sr. No.	Filing Date	Title	Atty Dock.
1 11/367,013	Mar. 1, 2006	Multiple Wavelength Sensor Emitters	MLR.002A
2 11/366,995	Mar. 1, 2006	Multiple Wavelength Sensor Equalization	MLR.003A
3 11/366,209	Mar. 1, 2006	Multiple Wavelength Sensor Substrate	MLR.004A
4 11/366,210	Mar. 1, 2006	Multiple Wavelength Sensor Interconnect	MLR.005A
5 11/366,833	Mar. 1, 2006	Multiple Wavelength Sensor Attachment	MLR.006A
6 11/366,997	Mar. 1, 2006	Multiple Wavelength Sensor Drivers	MLR.009A
7 11/367,034	Mar. 1, 2006	Physiological Parameter Confidence Measure	MLR.010A
8 11/367,036	Mar. 1, 2006	Configurable Physiological Measurement System	MLR.011A
9 11/367,033	Mar. 1, 2006	Noninvasive Multi-Parameter Patient Monitor	MLR.012A
10 11/367,014	Mar. 1, 2006	Noninvasive Multi-Parameter Patient Monitor	MLR.013A
11 11/366,208	Mar. 1, 2006	Noninvasive Multi-Parameter Patient Monitor	MLR.014A
12 13/412,428	Mar. 5, 2012	Noninvasive Multi-Parameter Patient Monitor	MLR.014C1
13 12/949,271	Nov. 18, 2010	Physiological Measurement System with Automatic Wavelength Adjustment	MLR.018A

The present application incorporates the foregoing disclosures herein by reference.

FIELD OF THE DISCLOSURE

The present disclosure relates to the field of noninvasive patient monitors. More specifically, the disclosure relates to monitors displaying measurements derived using signals from optical sensors.

2

BACKGROUND

Spectroscopy is a common technique for measuring the concentration of organic and some inorganic constituents of a solution. The theoretical basis of this technique is the Beer-Lambert law, which states that the concentration c_i of an absorbent in solution can be determined by the intensity of light transmitted through the solution, knowing the path-length d_{λ} , the intensity of the incident light $I_{0,\lambda}$, and the extinction coefficient $\epsilon_{i,\lambda}$ at a particular wavelength λ . In generalized form, the Beer-Lambert law is expressed as:

$$I_{\lambda} = I_{0,\lambda} e^{-d_{\lambda} \mu_{0,\lambda}} \quad (1)$$

$$\mu_{0,\lambda} = \sum_{i=1}^n \epsilon_{i,\lambda} \cdot c_i \quad (2)$$

where $\mu_{0,\lambda}$ is the bulk absorption coefficient and represents the probability of absorption per unit length. The minimum number of discrete wavelengths that are required to solve Equations 1-2 are the number of significant absorbers that are present in the solution.

A practical application of this technique is pulse oximetry, which utilizes a noninvasive sensor to measure oxygen saturation (SpO_2) and pulse rate. In general, the sensor has light emitting diodes (LEDs) that transmit optical radiation of red and infrared wavelengths into a tissue site and a detector that responds to the intensity of the optical radiation after absorption (e.g., by transmission or transreflectance) by pulsatile arterial blood flowing within the tissue site. Based on this response, a processor determines measurements for SpO_2 , pulse rate, and can output representative plethysmographic waveforms. Thus, "pulse oximetry" as used herein encompasses its broad ordinary meaning known to one of skill in the art, which includes at least those noninvasive procedures for measuring parameters of circulating blood through spectroscopy. Moreover, "plethysmograph" as used herein (commonly referred to as "photoplethysmograph"), encompasses its broad ordinary meaning known to one of skill in the art, which includes at least data representative of a change in the absorption of particular wavelengths of light as a function of the changes in body tissue resulting from pulsing blood.

Pulse oximeters capable of reading through motion induced noise are available from Masimo Corporation ("Masimo") of Irvine, Calif. Moreover, portable and other oximeters capable of reading through motion induced noise are disclosed in at least U.S. Pat. Nos. 6,770,028, 6,658,276, 6,157,850, 6,002,952, and 5,769,785. Read which are owned by Masimo, and are incorporated by reference herein. Such reading through motion oximeters have gained rapid acceptance in a wide variety of medical applications, including surgical wards, intensive care and neonatal units, general wards, home care, physical training, and virtually all types of monitoring scenarios.

SUMMARY OF THE DISCLOSURE

Despite the success of read through motion oximeter systems, there is a need to provide patient monitors capable of displaying multiple physiological parameters, other than or in addition to SpO_2 , plethysmograph waveforms, or pulse rates. For example, in accessing a patient's condition, caregivers often desire knowledge of other blood constituents, including for example, a percent value for arterial carbon monoxide saturation ("HbCO") or a percent value for methemoglobin

3

saturation ("HbMet") or the like. For example, in an embodiment, the display advantageously displays one or more of the following: pulse rate, plethysmograph waveform data, perfusion index, values of blood constituents in body tissue, including for example, HbCO, HbMet, total hemoglobin ("Hbt"), arterial oxygen saturation ("SpO₂"), fractional arterial oxygen saturation ("SpaO₂"), or the like. In other embodiments, the monitor may advantageously and accurately determine values for one or more of HbO₂, Hb, blood glucose, water, the presence or absence of therapeutic drugs (aspirin, Dapson, nitrates, or the like) or abusive/recreational drugs (methamphetamine, alcohol, steroids, or the like), concentrations of carbon dioxide ("CO₂") or oxygen ("O"), pH levels, bilirubin, perfusion quality, signal quality or the like. Accordingly, the present disclosure includes a multi-parameter patient monitor capable of determining one or more of the foregoing parameters, other than or in addition to, SpO₂, plethysmograph waveforms, or perfusion quality index.

In an embodiment, the display of a noninvasive multi-parameter patient monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display area or real estate. In an embodiment, a user may cycle different parameter values through an area of the display common to both parameters even when one parameter is shifted, through, for example, actuation of a user input key. The patient monitor may also display different parameters as color-coded. For example, when the following measured parameters are within "normal" ranges, SpO₂ may be displayed red, pulse rate (BPM) may be displayed green, HbCO may be displayed orange, HbMet may be displayed blue, or the like. In an embodiment, measured values of SpO₂ may be displayed in white, BPM may be displayed in yellow green or aquamarine, P_{IT}™ may be displayed in violet, Hbt may be displayed in grass green, HbMet may be displayed in blue or light blue, HbCO may be displayed in orange, and SpaO₂ may be displayed in electric blue.

Moreover, parameter trend data may also be displayed using the same or similar color coding, especially when multiple trends are displayed on one or more display graphs. In addition, more coarse or gross parameter indications may be displayed for quick reference to indicate to a caregiver whether any of a variety of monitored parameters, such as, for example, SpO₂, HbCO or HbMet is within acceptable ranges. The monitor may advantageously include additional display information, such as, for example, parametric displays where one parameter is displayed as a function of another, three dimensional displays (for example, extending a parametric display along time or an additional parameter), directional indicators predicting where a parameter is likely heading or reporting a general direction a parameters has been trending, or the like.

In addition to the foregoing, caregivers often desire to more closely monitor parameters that are close to, approaching, or beyond normal safe thresholds. In an embodiment, the patient monitor provides an indication that the caregiver should change display modes to view more critical monitored parameters. In alternative embodiments, the patient monitor automatically changes display modes to show parameters moving closer to or beyond normal thresholds.

In an embodiment, the patient monitor includes an audible or visual indication of a type of sensor communicating with the monitor. For example, the monitor may determine how many wavelengths a particular attached sensor will emit through communication with memory devices associated with the attached sensor or cable.

4

Additional embodiments include audio or visual alarms for each of multiple monitored parameters, combinations of parameters, an indication of perfusion in the tissue of the measurement site, an indication of the confidence the signal processing has in its output measurements, or the like.

For purposes of summarization, certain aspects, advantages and novel features are described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features need to be present in any particular embodiment.

BRIEF DESCRIPTION OF THE DRAWINGS

The drawings and the associated descriptions are provided to illustrate embodiments of the disclosure and not to limit the scope of the claims.

FIG. 1 illustrates a block diagram of an exemplary embodiment of a patient monitoring system including a sensor and a multi-parameter patient monitor.

FIG. 2 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor capable of displaying at least HbCO, such as, for example, the patient monitor of FIG. 1.

FIG. 3 illustrates an exemplary display of the patient monitor of FIG. 2.

FIG. 4 illustrates the display of FIG. 3 showing measured values of SpO₂, BPM, perfusion, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.

FIG. 5 illustrates the display of FIG. 3 showing measured values of HbCO, perfusion, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.

FIG. 6 illustrates the display of FIG. 3 showing measured values of SpO₂, HbCO, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1.

FIG. 7 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor capable of displaying at least HbCO and HbMet, such as, for example, the patient monitor of FIG. 1.

FIG. 8 illustrates an exemplary display of the patient monitor of FIG. 7.

FIG. 9 illustrates the display of FIG. 8 showing measured values of SpO₂, BPM, HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.

FIG. 10 illustrates the display of FIG. 8 showing measured values of HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1.

FIG. 11A illustrates a perspective view of an exemplary noninvasive multi-parameter patient monitor such as, for example, the patient monitor of FIG. 1.

FIGS. 11B-11H illustrate display screens of the patient monitor of FIG. 11A.

DETAILED DESCRIPTION OF PREFERRED AND ALTERNATIVE EMBODIMENTS

Embodiments of the present disclosure include a portable or other multi-parameter patient monitor capable of determining multiple physiological parameters from one or more signals output from one or more light sensitive detectors capable of detecting light attenuated by body tissue carrying pulsing blood. For example, in an embodiment, the monitor advantageously and accurately determines a wide variety of physiological parameters or other calculations as discussed above.

5

In an embodiment, the display of patient monitor advantageously includes a plurality of display modes enabling more parameter data to be displayed than the available physical display real estate. For example, the patient monitor may include one or more user input keys capable of toggling through measurement data. In an embodiment, the displays include mode indicators providing caregivers easily identifiable visual queues, such as LED's, text, icons, or other indicia providing readily identifiable queues as to which parameter is being displayed. In an embodiment, the display may shift, may be parameter color-coded, or the like to further ensure quick comprehension of which measured parameter is the displayed parameter. For example, in an embodiment, the monitor displays SpO₂ in white, pulse rate (BPM) in green, HbCO in orange, and HbMet in blue when the respective measured parameter is within a "normal" range.

In an embodiment, the patient monitor provides an indication that the caregiver should change display modes to view more critical or time sensitive measured parameters, specific caregiver selected parameters, or the like. For example, the patient monitor may advantageously sound audio or visual alarms that alert the caregiver to particular one or more of worsening parameters, parameters changing in a predetermined pattern or rate, parameters stabilizing below user defined or safe thresholds, caregiver selected parameters, or the like. The monitor may also use alerts that provide audio or visual indications of the severity of the condition, severity of the change, or the like. In alternative embodiments, the patient monitor may automatically change display modes when a particular parameter crosses one or more thresholds. For example, a patient monitor may be displaying a first parameter, such as a plethysmograph, and upon determining measurements indicating that HbMet is trending toward an alarm condition, the monitor may automatically switch from displaying the first parameter to the alarming parameter, or in this case, a trend of the alarming parameter.

In an embodiment, a switch is provided to allow a user to switch displays to view an alarming measurement. In an embodiment, during an alarm condition, a parameter display may switch to a trend graph in the same or different color, line weight, flash, flash rate, intensity, size, or the like.

The patient monitor may also include one or more displays capable of displaying trend data for any one or more of the monitored or derived patient parameters. For example, the trend data may be displayed in graph form, may include multiple trend lines, each representing a different monitored or derived patient parameter. Moreover, each trend line may be color-coded to facilitate quick comprehension of which trend line represents which measured parameter. However, an artisan will recognize from the disclosure herein a large number of identification techniques including color-coding, identifying text, or the like. Additionally, user input may toggle displayed trend data, may select which parameters to display simultaneously, or the like.

In an embodiment, the patient monitor includes an audible or visual indication of a type of sensor communicating with the monitor. For example, the patient monitor may provide a particular audio or visual indication, such as a beep, LED activation, graphic activation, text messages, voice messages, or the like, to indicate communication with or connection to an approved sensor, patient cable, combination, or the like. In an embodiment, the indication may change based on the manufacturer, type of sensor recognized or not recognized, type of patient, type of physiological parameters measurable with the attached sensor, or the like. Additional embodiments include an indication of perfusion in the tissue of the mea-

6

surement site and an indication of the confidence the signal processing has in its output measurements or input signal quality.

To facilitate an understanding of the disclosure, the remainder of the description references exemplary embodiments illustrated in the drawings. Moreover, in this application, reference is made to many blood parameters. Some references that have common shorthand designations are referenced through such shorthand designations. For example, as used herein, HbCO designates carboxyhemoglobin, HbMet designates methemoglobin, and Hbt designates total hemoglobin. Other shorthand designations such as COHb, MetHb, and tHb are also common in the art for these same constituents. These constituents are generally reported herein in terms of a percentage, often referred to as saturation, relative concentration or fractional saturation. Total hemoglobin is generally reported as a concentration in g/dL. The use of the particular shorthand designators presented in this application does not restrict the term to any particular manner in which the designated constituent is reported.

FIG. 1 illustrates a block diagram of an exemplary embodiment of a patient monitoring system **100**. As shown in FIG. 1, the system **100** includes a patient monitor **102** comprising a processing board **104** and a host instrument **108**. The processing board **104** communicates with a sensor **106** to receive one or more intensity signal(s) indicative of one or more parameters of tissue of a patient. The processing board **104** also communicates with a host instrument **108** to display determined values calculated using the one or more intensity signals. According to an embodiment, the board **104** comprises processing circuitry arranged on one or more printed circuit boards capable of installation into the monitor **102**, or capable of being distributed as some or all of one or more OEM components for a wide variety of host instruments monitoring a wide variety of patient information. In an embodiment, the processing board **102** comprises a sensor interface **110**, a digital signal processor and signal extractor ("DSP" or "processor") **112**, and an instrument manager **114**. In general, the sensor interface **110** converts digital control signals into analog drive signals capable of driving sensor emitters, and converts composite analog intensity signal(s) from light sensitive detectors into digital data.

In an embodiment, the sensor interface **110** manages communication with external computing devices. For example, in an embodiment, a multipurpose sensor port (or input/output port) is capable of connecting to the sensor **106** or alternatively connecting to a computing device, such as a personal computer, a PDA, additional monitoring equipment or networks, or the like. When connected to the computing device, the processing board **104** may upload various stored data for, for example, off-line analysis and diagnosis. The stored data may comprise trend data for any one or more of the measured parameter data, plethysmograph waveform data acoustic sound waveform, or the like. Moreover, the processing board **104** may advantageously download from the computing device various upgrades or executable programs, may perform diagnosis on the hardware or software of the monitor **102**. In addition, the processing board **104** may advantageously be used to view and examine patient data, including raw data, at or away from a monitoring site, through data uploads/downloads, or network connections, combinations, or the like, such as for customer support purposes including software maintenance, customer technical support, and the like. Upgradable sensor ports are disclosed in copending U.S. application Ser. No. 10/898,680, filed on Jul. 23, 2004, titled "Multipurpose Sensor Port," incorporated by reference herein.

7

As shown in FIG. 1, the digital data is output to the DSP 112. According to an embodiment, the DSP 112 comprises a processing device based on the Super Harvard ARChitecture ("SHARC"), such as those commercially available from Analog Devices. However, a skilled artisan will recognize from the disclosure herein that the DSP 112 can comprise a wide variety of data and/or signal processors capable of executing programs for determining physiological parameters from input data. In particular, the DSP 112 includes program instructions capable of receiving multiple channels of data related to one or more intensity signals representative of the absorption (from transmissive or reflective sensor systems) of a plurality of wavelengths of emitted light by body tissue. In an embodiment, the DSP 112 accepts data related to the absorption of eight (8) wavelengths of light, although an artisan will recognize from the disclosure herein that the data can be related to the absorption of two (2) to sixteen (16) or more wavelengths.

FIG. 1 also shows the processing board 104 including the instrument manager 114. According to an embodiment, the instrument manager 114 may comprise one or more microcontrollers controlling system management, including, for example, communications of calculated parameter data and the like to the host instrument 108. The instrument manager 114 may also act as a watchdog circuit by, for example, monitoring the activity of the DSP 112 and resetting it when appropriate.

The sensor 106 may comprise a reusable clip-type sensor, a disposable adhesive-type sensor, a combination sensor having reusable and disposable components, or the like. Moreover, an artisan will recognize from the disclosure herein that the sensor 106 can also comprise mechanical structures, adhesive or other tape structures, Velcro wraps or combination structures specialized for the type of patient, type of monitoring, type of monitor, or the like. In an embodiment, the sensor 106 provides data to the board 104 and vice versa through, for example, a patient cable. An artisan will also recognize from the disclosure herein that such communication can be wireless, over public or private networks or computing systems or devices, or the like.

As shown in FIG. 1, the sensor 106 includes a plurality of emitters 116 irradiating the body tissue 118 with differing wavelengths of light, and one or more detectors 120 capable of detecting the light after attenuation by the tissue 118. In an embodiment, the emitters 116 comprise a matrix of eight (8) emission devices mounted on a flexible substrate, the emission devices being capable of emitting eight (8) differing wavelengths of light. In other embodiments, the emitters 116 may comprise twelve (12) or sixteen (16) emitters, although other numbers of emitters are contemplated, including two (2) or more emitters. As shown in FIG. 1, the sensor 106 may include other electrical components such as, for example, a memory device 122 comprising an EPROM, EEPROM, ROM, RAM, microcontroller, combinations of the same, or the like. In an embodiment, other sensor components may include a temperature determination device 123 or other mechanisms for, for example, determining real-time emission wavelengths of the emitters 116.

The memory 122 may advantageously store some or all of a wide variety data and information, including, for example, information on the type or operation of the sensor 106; type or identification of sensor buyer or distributor or groups of buyer or distributors, sensor manufacturer information, sensor characteristics including the number of emitting devices, the number of emission wavelengths, data relating to emission centroids, data relating to a change in emission characteristics based on varying temperature, history of the sensor tempera-

8

ture, current, or voltage, emitter specifications, emitter drive requirements, demodulation data, calculation mode data, the parameters for which the sensor is capable of supplying sufficient measurement data (e.g., HpCO, HpMet, HbT, or the like), calibration or parameter coefficient data, software such as scripts, executable code, or the like, sensor electronic elements, whether the sensor is a disposable, reusable, multi-site, partially reusable, partially disposable sensor, whether it is an adhesive or non-adhesive sensor, whether the sensor is a reflectance, transmittance, or transreflectance sensor, whether the sensor is a finger, hand, foot, forehead, or ear sensor, whether the sensor is a stereo sensor or a two-headed sensor, sensor life data indicating whether some or all sensor components have expired and should be replaced, encryption information, keys, indexes to keys or hash functions, or the like, monitor or algorithm upgrade instructions or data, some or all of parameter equations, information about the patient, age, sex, medications, and other information that may be useful for the accuracy or alarm settings and sensitivities, trend history, alarm history, or the like. In an embodiment, the monitor may advantageously store data on the memory device, including, for example, measured trending data for any number of parameters for any number of patients, or the like, sensor use or expiration calculations, sensor history, or the like.

FIG. 1 also shows the patient monitor 102 including the host instrument 108. In an embodiment, the host instrument 108 communicates with the board 104 to receive signals indicative of the physiological parameter information calculated by the DSP 112. The host instrument 108 preferably includes one or more display devices 124 capable of displaying indicia representative of the calculated physiological parameters of the tissue 118 at the measurement site. In an embodiment, the host instrument 108 may advantageously comprise a handheld housing capable of displaying one or more of a pulse rate, plethysmograph data, perfusion quality such as a perfusion quality index ("PITM"), signal or measurement quality ("SQ"), values of blood constituents in body tissue, including for example, SpO₂, HbCO, HbMet, Hbt, or the like. In other embodiments, the host instrument 108 is capable of displaying values for one or more of Hbt, Hb, blood glucose, bilirubin, or the like. The host instrument 108 may be capable of storing or displaying historical or trending data related to one or more of the measured values, combinations of the measured values, plethysmograph data, or the like. The host instrument 108 also includes an audio indicator 126 and user input device 128, such as, for example, a keypad, touch screen, pointing device, voice recognition device, or the like.

In still additional embodiments, the host instrument 108 includes audio or visual alarms that alert caregivers that one or more physiological parameters are falling below predetermined safe thresholds. The host instrument 108 may include indications of the confidence a caregiver should have in the displayed data. In a further embodiment, the host instrument 108 may advantageously include circuitry capable of determining the expiration or overuse of components of the sensor 106, including, for example, reusable elements, disposable elements, or combinations of the same.

Although described in terms of certain embodiments, other embodiments or combination of embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, the monitor 102 may comprise one or more monitoring systems monitoring parameters, such as, for example, vital signs, blood pressure, ECG or EKG, respiration, glucose, bilirubin, or the like. Such systems may combine other information with intensity-derived information to

9

influence diagnosis or device operation. Moreover, the monitor **102** may advantageously include an audio system, preferably comprising a high quality audio processor and high quality speakers to provide for voiced alarms, messaging, or the like. In an embodiment, the monitor **102** may advantageously include an audio out jack, conventional audio jacks, headphone jacks, or the like, such that any of the display information disclosed herein may be audiblized for a listener. For example, the monitor **102** may include an audible transducer input (such as a microphone, piezoelectric sensor, or the like) for collecting one or more of heart sounds, lung sounds, trachea sounds, or other body sounds and such sounds may be reproduced through the audio system and output from the monitor **102**. Also, wired or wireless communications (such as Bluetooth or WiFi, including IEEE 801.11a, b, or g), mobile communications, combinations of the same, or the like, may be used to transmit the audio output to other audio transducers separate from the monitor **102**.

For example, patterns or changes in the continuous noninvasive monitoring of intensity-derived information may cause the activation of other vital sign measurement devices, such as, for example, blood pressure cuffs.

FIG. 2 illustrates a perspective view of an exemplary handheld noninvasive multi-parameter patient monitor **200**, such as, for example, the patient monitor **102** of FIG. 2. Patient monitors **200** exhibiting combinations of many of the features described herein are advantageously commercially available from Masimo under the brand name "Rad 57c." As shown in FIG. 1, the monitor **200** includes a patient cable connector **202** capable of mechanical mating with a patient cable to establish communication between the board **104** and the sensor **106**. In an embodiment, the connector **202** comprises a multipurpose cable connector such as that disclosed in the incorporated U.S. application Ser. No. 10/898,680, titled "Multipurpose Sensor Port," disclosing communication between the board **104** and an external computing device.

The monitor **202** also comprises a HbCO indicator **204** advantageously providing a visual queue that a HbCO capable sensor is properly connected through the connector **202**. For example, the HbCO indicator **204** may advantageously activate when a sensor is connected that communicates sufficient information to determine HbCO, such as, for example, a sensor capable of emitting sufficient different wavelengths of light, a sensor storing sufficient data on the memory **122**, a sensor having appropriate encryption data or key, combinations of the same, or the like. For example, in an embodiment, the processor **112** may receive information from a memory **122** indicating a number of available LED wavelengths for the attached sensor. Based on the number of wavelengths, or other information stored on the memory **122**, the processor **112** may determine whether an HbCO-ready sensor has been attached to the monitor **200**. An artisan will also recognize from the disclosure herein that the HbCO indicator **204** may advantageously comprise a HbMet indicator, Hbt indicator, or the like, which activates to a predetermined color associated with a parameter, or any color, or deactivates the same, to convey a type of attached sensor. Moreover, the artisan will recognize from the disclosure herein other parameters that may use other sensor components and the monitor **200** may include indicators capable of indicating communication with those types of sensors.

In an embodiment, the monitor **200** may also audibly indicate the type of sensor connected. For example, the monitor **200** may emit predetermined number or frequency of beeps associated with recognition of a particular sensor, a particular manufacturer, failure to recognize the sensor, or the like. Moreover, the sensor type may be indicative of the compo-

10

nentry, such as, for example, whether the sensor produces sufficient data for the determination of HbCO, HbMet, Hbt and SpO₂, SpO₂ only, SpO₂ and HbMet, any combination of the foregoing or other parameters, or the like. Additionally, the sensor type may be indicative of specific sensors designed for a type of patient, type of patient tissue, or the like. In other embodiments, the monitor **200** may announce the type of connector through speaker **236**.

An artisan will also recognize from the disclosure herein that other mechanical (such as keys), electrical, or combination devices may inform the monitor **202** of the type of attached sensor. In an embodiment, the processor **112** also may select to drive less emitters that are currently available, such as, for example, in the presence of low noise and when power consumption is an issue.

The monitor **202** also comprises a multi-mode display **206** capable of displaying, for example, measurements of SpO₂ and HbCO (or alternatively, HbMet). In an embodiment, the display **206** has insufficient space or display real estate to display the many parameters capable of being measured by the monitor **200**. Thus, the multi-mode display **206** may advantageously cycle through two or more measured parameters in an area common to both parameters even when shifted. In such embodiments, the monitor **200** may also advantageously include parameter indicators **208**, **210**, providing additional visual queues as to which parameter is currently displayed. In an embodiment, the display may also cycle colors, flash rates, or other audio or visual queues providing readily identifiable information as to which measured parameter is displayed. For example, when the multi-mode display **206** displays measured values of SpO₂ that are normal, the numbers may advantageously appear in green, while normal measured values of HbCO may advantageously appear in orange, and normal measured values of HbMet may appear in blue. Moreover, in an embodiment, the display **206** flashes at a predefined rate when searching for saturation and at another predefined rate when a signal quality is below a predetermined threshold.

The monitor **202** also comprises a HbCO bar **212** where in an embodiment a plurality of LED's activate from a bottom toward a top such that the bar "fills" to a level proportional to the measured value. For example, the bar **212** is lowest when the dangers from carbon monoxide poisoning are the least, and highest when the dangers are the greatest. The bar **212** includes indicia **214** that provide an indication of the severity of carbon monoxide saturation in a patient's blood. As shown in FIG. 2, the bar **212** and the indicia **214** continuously indicate the concentration of HbCO in about 5% increments. The indicia **214** indicate a measurement of HbCO saturation percentage between about 0 and about 50% with a granularity of about 5%. However, an artisan will also recognize from the disclosure herein a wide variety of ranges and granularities could be used, the indicia **214** could be electronically displayed in order to straightforwardly increase or decrease resolution, or the like. For example, HbCO may advantageously be displayed with greater resolution than about ±5% in a lower portion of the scale. For example, an HbCO bar may advantageously include a scale of about <3%, about 6%, about 9%, about 12%, about 15%, about 20%, about 25%, about 30%, about 35%, and about >40%.

As is known in the art, carbon monoxide in the blood can lead to serious medical issues. For example and depending upon the particular physiology of a patient, about 10% carbon monoxide saturation can lead to headaches, about 20% can lead to throbbing headaches, or dyspnea on exertion, about 30% can lead to impaired judgment, nausea, dizziness and/or vomiting, visual disturbance, or fatigue, about 40% can lead

11

to confusion and syncope, and about 50% and above can lead to comas, seizures, respiratory failure and even death.

In an embodiment, the bar **212** is the same or similar color as the multi-mode display **206** when displaying HbCO. In other embodiments, the bar **212** is lowest and green when the dangers from carbon monoxide poisoning are the least, and highest and red when the dangers are the greatest. In an embodiment, as HbCO increases, the entire bar **212** may advantageously change color, such as, for example, from green to red, to provide a clear indication of deepening severity of the condition. In other embodiments, the bar **212** may advantageously blink or flash, an audio alarm may beep or provide a continuation or rise in pitch or volume, or the like to alert a caregiver of deepening severity. Moreover, straightforward to complex alarm rules may be implemented to reduce false alarms based on, for example, knowledge of the physiological limitations on the rate of change in HbCO or the like.

Additionally, the monitor **200** may be capable of storing and outputting historical parameter data, display trend traces or data, or the like. Although the foregoing bar **212** has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein.

FIG. **2** also shows the monitor **200** including a pulse display **216** displaying measured pulse rate in beats per minute ("BPM"). In an embodiment, the display **212** flashes when searching for a pulse. The pulse display **216** advantageously displays measured pulse rates from about zero (0) to about two hundred and forty (240) BPM. Moreover, when the measured pulse rates are considered normal, the pulse display **216** is advantageously green. Similar to other displays associated with the monitor **200**, the pulse display **216** may employ a variety of color changes, audio alarms, or combinations of the same to indicate measured BPM below predetermined safe thresholds. In an embodiment, the pulse rate display **216** displays the measured pulse rate during the display of SpO₂ and displays message data during the display of other parameters. For example, during the display of HbCO, the display **216** may advantageously display the term "CO." In an embodiment, the display of the message data may be in the same or similar color as the other displays. For example, in an embodiment, the multi-mode display **206**, the bar **212**, and the pulse display **216** may all display data or messages in orange when the multi-mode display **206** displays measured HbCO values.

FIG. **2** also illustrates the monitor **200** comprising user input keys **218**, including a HbCO button **220**, mode/enter button **222**, next button **224**, power on/off button **226**, up/down button **228**, and alarm silence button **230**. In an embodiment, activation of the HbCO button **220** toggles the measured value displayed in the multi-mode display **206**. For example, activation of the HbCO button **220** toggles the multi-mode display **206** from displaying measured values of SpO₂ to HbCO for about ten (10) seconds. Activation of the mode/enter button **222** or the next button **224** during the ten (10) second period returns the multi-mode display **206** back to SpO₂. A skilled artisan will also recognize that activation of the HbCO button **220** may advantageously toggle through a plurality of measured values, and that such values may be displayed for short segments and then return to SpO₂, may remain displayed until further activation of the button **220**, or the like.

Activation of the mode/enter button **222** cycles through various setup menus allowing a caregiver to select or activate certain entries within the menu setup system, including alarm threshold customizations, or the like. Activation of the next button **224** can move through setup options within the menu

12

setup system and in an embodiment is not active during normal patient monitoring. For example, a caregiver may activate the mode/enter button **222** and the next button **224** to specify high and low alarm thresholds for one or more of the measured parameters, to specify device sensitivity, trend settings, display customizations, color code parameters, or the like. In an embodiment, the high alarm setting for SpO₂ can range from about two percent (2%) to about one hundred percent (100%) with a granularity of about one percent (1%). The low alarm setting for SpO₂ can range from about one percent (1%) to about one hundred percent (100%) with a granularity of about one percent (1%). Moreover, the high alarm setting for pulse rate can range from about thirty (30) BPM to about two hundred and forty (240) BPM with a granularity of about five (5) BPM. The low alarm setting for pulse rate can range from about twenty five (25) BPM to about two hundred and thirty five (235) BPM with a granularity of about five (5) BPM. Other high and low ranges for other measured parameters will be apparent to one of ordinary skill in the art from the disclosure herein.

In a further embodiment, a caregiver may activate the mode/enter button **222** and the next button **224** to specify device sensitivity, such as, for example, device averaging times, probe off detection, whether to enable fast saturation calculations, or the like. Various embodiments of fast saturation calculations are disclosed in U.S. patent application Ser. No. 10/213,270, filed Aug. 5, 2002, titled "Variable Indication Estimator" and incorporated by reference herein. Using the menus, a caregiver may also advantageously enter appropriate information governing trend collection on one or more of the measured parameters, input signals, or the like.

FIG. **2** also shows the power on/off button **226**. Activation of the power on/off button **226** activates and deactivates the monitor **200**. In an embodiment, press-and-hold activation for about two (2) seconds shuts the monitor **200** off. In an additional embodiment, activation of the on/off button **226** advantageously initiates detection of a type of attached sensor. For example, activation of the on/off button **226** may advantageously cause the monitor **200** to read information from a memory on an attached sensor and determine whether sufficient wavelengths exist on the sensor to determine one or more of the physiological parameters discussed in the foregoing.

An artisan will recognize from the disclosure herein that the on/off button **226** may advantageously cause an electronic determination of whether to operate in at powers consisted with the U.S. (60 Hz) or another nationality (50 Hz). In an embodiment, such automatic determination and switching is removed from the monitor **200** in order to reduce a likelihood of problematic interfering crosstalk caused by such power switching devices.

Activation of the up/down button **228** may advantageously adjust the volume of the pulse beep tone. Additionally, activation of the up/down button **228** within the menu setup system, causes the selection of values with various menu options.

Moreover, activation of the alarm silence button **230** temporarily silences audio alarms for a predetermined period, such as, for example, about one hundred and twenty (120) seconds. A second activation of the alarm silence button **230** mutes (suspends) the alarm indefinitely, while a third activation returns the monitor **200** to standard alarm monitoring. FIG. **2** also shows the alarm silence button **230** includes an alarm silenced indicator **232**. The alarm silenced indicator **232** may advantageously flash to indicate one or more alarms are temporarily silenced, may illuminate solid to indicate the

13

alarms have been muted, or the like. Moreover, an artisan will recognize from the disclosure herein a wide variety of alarm silencing methodologies.

The monitor **202** also includes a battery level indicator **234** indicating remaining battery life. In the illustrated embodiment, four LED's indicate the status of the battery by incrementally deactivating to indicate proportionally decreasing battery life. In an embodiment, the four LED's may also change color as the battery charge decreases, and the final LED may begin to flash to indicate that the caregiver should replace the batteries.

FIG. **2** also shows the monitor **202** including an audio transducer or speaker **236**. The speaker **236** advantageously provides audible indications of alarm conditions, pulse tone and feedback for key-presses, or the like. Moreover, the monitor **202** includes a low signal quality indicator ("SQ" or "SIQ™") **238**. The signal IQ indicator **238** activates to inform a caregiver that a measured value of the quality of the incoming signal is below predetermined threshold values. For example, in an embodiment, the measured value for signal IQ is at least partially based on an evaluation of the plethysmograph data's correspondence to predetermined models or characteristics of physiological signals. In an embodiment, the signal IQ indicator **238** output may be associated with the displayed parameter. For example, the output may be associated with one threshold for the display of SpO₂ and another for the display of other parameter data.

The monitor **202** also comprises a perfusion quality index ("PI™") bar **240** (which quantifies the measure of perfusion of the patient) where in an embodiment a plurality of LED's activate from a bottom toward a top such that the bar "fills" to a level proportional to the measured value. In one embodiment, the PI™ bar **240** shows a static value of perfusion for a given time period, such as, for example, one or more pulses. In another embodiment, or functional setting, the PI™ bar **240** may advantageously pulse with a pulse rate, may hold the last reading and optionally fade until the next reading, may indicate historical readings through colors or fades, or the like. Additionally, the PI™ bar **240** may advantageously change colors, flash, increasingly flash, or the like to indicate worsening measured values of perfusion.

The PI™ bar **240** can be used to simply indicate inappropriate occlusion due, for example, to improper attachment of the sensor **106**. The PI™ bar **240** can also be used as a diagnostic tool during low perfusion for the accurate prediction of illness severity, especially in neonates. Moreover, the rate of change in the PI™ bar **240** can be indicative of blood loss, sleep arousal, severe hypertension, pain management, the presence or absence of drugs, or the like. According to one embodiment, the PI™ bar **240** values may comprise a measurement of the signal strength of the arterial pulse as a percentage of the total signal received. For example, in one preferred embodiment, the alternating portion of at least one intensity signal from the sensor **106** may advantageously be divided by the static portion of the signal. For example, an infrared intensity signal may advantageously be used as it is less subjective to noise.

In an embodiment, a measurement below about 1.25% may indicate medical situations in need of caregiver attention, specifically in monitored neonates. Because of the relevance of about 1.25%, the PI™ bar **240** may advantageously include level indicia **242** where the indicia **242** swap sides of the PI™ bar **240**, thus highlighting any readings below about that threshold. Moreover, behavior of the PI™ bar **240**, as discussed above, may advantageously draw attention to monitored values below such a threshold.

14

As discussed above, the monitor **200** may include output functionality that outputs, for example, trend perfusion data, such that a caregiver can monitor measured values of perfusion over time. Alternatively or additionally, the monitor **200** may display historical trace data on an appropriate display indicating the measured values of perfusion over time. In an embodiment, the trend data is uploaded to an external computing device through, for example, the multipurpose sensor connector **202** or other input output systems such as USB, serial or parallel ports or the like.

The monitor **200** also includes an alarm indicator **244** capable of providing visual queues of the status of one or more of the measured parameters. For example, the alarm indicator **244** may advantageously be green when all of the measured parameters are within normal conditions, may gradually fade to red, may flash, increasing flash, or the like, as one or more of the measured values approaches or passes predetermined thresholds. In an embodiment, the alarm indicator **244** activates when any parameter falls below an associated threshold, thereby advantageously informing a caregiver that perhaps a nondisplayed parameters is at an alarm condition. In another embodiment, the alarm indicator **244** may indicate the status of the parameter displayed on the multi-mode display **206**. In an embodiment, the speaker **236** may sound in conjunction with and/or in addition to the indicator **244**. Moreover, in an embodiment, an alarming parameter may automatically be displayed, may be emphasized, flashed, colored, combinations of the same or the like to draw a user's attention to the alarming parameter.

Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein.

FIG. **3** illustrates an exemplary display of the patient monitor **200**. As shown in FIG. **3**, the display includes the multi-mode display **206**, the pulse rate display **216**, parameter indicators **208**, **210**, the HbCO bar **212** and indicator **204**, the PI™ bar **240**, and the alarm indicator **244**. In an embodiment, the multi-mode display **206** and the pulse rate display **216** each comprise a plurality of seven segment displays **302** capable of displaying alpha-numeric information. As disclosed in the foregoing, the exemplary display may advantageously include color-coded parameter displays. Moreover, the exemplary display may include color progressions, flashing, flashing progressions, audible alarms, audible progressions, or the like, indicating worsening measured values of physiological data. In addition, in an embodiment, some or all of the displays may flash at a first rate to indicate attempts to acquire data when actual measured values are unavailable. Moreover, some or all of the display may flash at a second rate to indicate low signal quality where confidence is decreasing that the measured values reflect actual physiological conditions.

FIG. **4** illustrates the display of FIG. **3** showing measured values of SpO₂, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. **1**. As shown in FIG. **4**, the multi-mode display **206** is displaying a percentage value of SpO₂, and the pulse rate display **216** is displaying a pulse rate in beats per minute. Accordingly, the parameter indicator **210** is activated to confirm the display of measured values of SpO₂. As disclosed in the foregoing, in an embodiment, the multi-mode display **206** is red, indicating blood oxygen measurements while the pulse rate display **216** is green, indicating normal values of a patient's pulse.

FIG. **4** also shows the PI™ bar **240** almost fully activated, representing good perfusion. In addition, the HbCO indicator **204** is showing communication with a sensor producing

15

insufficient data to determine measured values of additional parameters, such as, HbCO. In an embodiment, such sensors may comprise sensors capable of emitting light at about two (2) different wavelengths, may comprise sensors with insufficient data stored on a memory associated therewith, or the like.

FIG. 5 illustrates the display of FIG. 3 showing measured values of HbCO, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1. As shown in FIG. 5, the multi-mode display 206 is displaying a percentage value of HbCO, and the pulse rate display 216 is displaying an appropriate message indicating the HbCO measurement, such as, for example, "CO". Also, the multi-mode display 206 has shifted the data to the left to quickly and efficiently indicate that the displayed parameter is other than SpO₂. Accordingly, the parameter indicator 208 is also activated to confirm the display of measured values of HbCO. As disclosed in the foregoing, in an embodiment, the multi-mode display 206 and pulse rate display message 216 are orange.

FIG. 5 also shows the P_{ITM} bar 240 almost fully activated, representing good perfusion. In addition, the activation of the HbCO indicator 204 represents communication with a sensor capable of producing sufficient data to determine measured values of HbCO. In an embodiment, such sensors may comprise sensors capable of emitting light at about eight (8) or more different wavelengths; however, such sensors may comprise about two (2) or more different wavelengths. Moreover, such sensors may have appropriate data stored on a memory associated therewith, or the like. FIG. 5 also shows the HbCO measurement being about 20% (as illustrated on the HbCO bar 212 and multi-mode display 206) thereby indicating a potentially dangerous situation that if exacerbated, will become quite problematic. Therefore, the alarm indicator 244 is also activated, and in some embodiments, the speaker 236 as well.

FIG. 6 illustrates the display of FIG. 3 showing measured values of SpO₂, HbCO, BPM, perfusion, and type of sensor, according to an exemplary embodiment of the patient monitor of FIG. 1. In contrast to FIG. 4, FIG. 6 shows that the monitor 200 is communicating with a sensor capable of producing sufficient data to determine measured values of HbCO, even though the displayed values are that of SpO₂ and BPM. Thus, FIG. 6 shows the activation of the HbCO indicator 204, and the continuous monitoring of HbCO by the HbCO bar 212. FIG. 6 also shows a high value of HbCO, and therefore, the indication of an alarm condition by activation of the alarm indicator 244. In an embodiment, upon determination of an alarm condition on a nondisplayed parameter, the monitor 200 may advantageously provide an alarm indication through speaker and alarm indicator activation, automatic toggle to the nondisplayed parameter on the multi-mode display 206 for a defined or undefined time, or the like.

FIG. 7 illustrates a top elevation view of an exemplary handheld noninvasive multi-parameter patient monitor 700 capable of displaying at least HbCO and HbMet, such as, for example, the patient monitor of FIG. 1. Patient monitors exhibiting combinations of many of the features described herein are advantageously commercially available from Masimo under the brand name "Rad 57 cm." As shown in FIG. 7, the monitor 700 comprises a monitor similar to monitor 200 disclosed with reference to FIG. 2. Moreover, monitor 700 further includes a multi-mode display 706 capable of displaying, for example, measurements of HbMet and BPM. In an embodiment, the display 706 has insufficient space or display real estate to display the many parameters capable of being measured by the monitor 700. Thus, the multi-mode display 706 may advantageously cycle through two or more

16

measured parameters. In such embodiments, the monitor 700 may also advantageously include parameter indicators 708, 710, providing additional visual queues as to which parameter is currently displayed. In an embodiment, the display 706 may also cycle colors, flash rates, or other audio or visual queues providing readily identifiable information as to which measured parameter is displayed. For example, when the multi-mode display 706 displays measured values of BPM that are normal, the numbers may advantageously appear in green, while normal measured values of HbMet may appear in blue. Moreover, in an embodiment, the display 706 may flash at a predefined rate when searching for saturation and at another predefined rate when a signal quality is below a predetermined threshold.

FIG. 7 also illustrates the monitor 700 comprising user input keys 718, including an HbCO/HbMet button 220. In an embodiment, activation of the HbCO/HbMet button 720 toggles the measured value displayed in the multi-mode display 706. For example, activation of the HbCO/HbMet button 720 toggles the multi-mode display 206 from displaying measured values of SpO₂ and BPM, to HbCO and HbMet for about ten (10) seconds. Activation of the mode/enter button 222 or the next button 224 during the ten (10) second period returns the multi-mode display 706 back to SpO₂ and BPM. A skilled artisan will also recognize that activation of the HbCO/HbMet button 720 may advantageously toggle through a plurality of measured values, and that such values may be displayed for short segments and then return to SpO₂ and BPM, may remain displayed until further activation of the button 720, or the like.

The monitor 700 also comprises a coarser indication of HbMet through an HbMet bar 740. In an embodiment, a plurality of LED's activate from a bottom toward a top such that the bar "fills" to a level proportional to the measured value, with increments at about 0.5%, about 1%, about 2%, about 3%, about 4%, about 5%, about 7.5%, about 10%, about 15% and greater than about 20%, although an artisan will recognize from the disclosure herein other useful delineations. Additionally, the HbMet bar 740 may advantageously change colors, flash, increasingly flash, or the like to indicate worsening measured values of perfusion.

Although disclosed with reference to the HbMet bar 740, and artisan will recognize from the disclosure herein other coarse or even gross indications of HbMet, or any measured parameter. For example, a single LED may advantageously show green, yellow, and red, to indicate worsening coarse values of HbMet. Alternatively, a single LED may simply light to indicate an alarm or approaching alarm condition.

FIG. 8 illustrates an exemplary display of the patient monitor 700 of FIG. 7. As shown in FIG. 8, the display includes the multi-mode displays 206, 706, parameter indicators 208, 210, 708, 710, the HbCO bar 212 and indicator 204, the HbMet bar 740, and the alarm indicator 244. In an embodiment, the multi-mode display 706 is similar to multi-mode display 206, comprising a plurality of seven segment displays 302 capable of displaying alpha-numeric information, and capable of altering its display characteristics or aspects in a wide variety of configurations discussed with reference to the display 206.

FIG. 9 illustrates the display of FIG. 8 showing measured values of SpO₂, BPM, HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1. FIG. 9 also shows the HbMet bar 740 near the bottom and corresponding to about 1%, representing acceptable HbMet, while the HbCO bar 212 hovers at a dangerous near 20%. In addition, the HbCO indicator 204 is showing communication with a sensor producing sufficient data to determine measured values of additional parameters, such as,

17

HbMet, HbCO or the like. In an embodiment, such sensors may comprise sensors capable of emitting light of more than two (2) different wavelengths, preferably more than four (4) different wavelengths, and more preferably eight (8) or more different wavelengths.

FIG. 10 illustrates the display of FIG. 8 showing measured values of HbCO, HbMet, and type of sensor according to an exemplary embodiment of the patient monitor of FIG. 1. As shown in FIG. 10, the multi-mode display 706 is displaying a percentage value of HbMet that is shifted using the parameter indicator 708. The data has been advantageously shifted to the left to quickly and efficiently indicate that the displayed parameter is other than BPM. Accordingly, the parameter indicator 708 is also activated to confirm the display of measured values of HbMet. As disclosed in the foregoing, in an embodiment, the multi-mode display 706 is blue.

FIG. 10 also shows the HbMet bar 740 nearly empty, representing acceptable HbMet. In addition, the activation of the HbCO indicator 204 represents communication with a sensor capable of producing sufficient data to determine measured values of HbCO. In an embodiment, such sensors may have appropriate data stored on a memory associated therewith, or the like. FIG. 10 also shows the HbCO measurement being about 20% (as illustrated on the HbCO bar 212 and multi-mode display 206) thereby indicating a potentially dangerous situation that if exacerbated, will become quite problematic. Therefore, the alarm indicator 244 is also activated, and in some embodiments, the speaker 236 as well.

FIG. 11A illustrates a perspective view of an exemplary noninvasive multi-parameter patient monitor 1100, such as, for example, the patient monitor of FIG. 1. Moreover, FIGS. 11B-11E illustrate exemplary display screens of the patient monitor of FIG. 11A. As shown in FIGS. 11A-11B, an embodiment of the monitor 1100 includes a display 1101 showing a plurality of parameter data. For example, the display may advantageously comprise a CRT or an LCD display including circuitry similar to that available on oximeters commercially available from Masimo Corporation of Irvine, Calif. sold under the name Radical™, and disclosed in the U.S. patents referenced above and incorporated above. However, an artisan will recognize from the disclosure herein many commercially available display components capable of displaying multiple parameter data along with the ability to display graphical data such as plethysmographs, trend traces, and the like.

In an embodiment, the display includes a measured value of SpO₂ 1102, a measured value of pulse rate 1104 in BPM, a plethysmograph 1106, a measured value of HbCO 1108, a measured value of HbMet 1110, a measured value of a perfusion quality 1112, a measured value of Hbt 1114, and a derived value of fractional saturation "SpaO₂" 1116. In an embodiment, SpaO₂ comprises HbO₂ expressed as a percentage of the four main hemoglobin species, i.e., HbO₂, Hb, HbCO, and HbMet.

In an embodiment, one or more of the foregoing parameter includes trending or prediction indicators 1118 showing the current trend or prediction for that corresponding parameter. In an embodiment, the indicators 1118 may advantageously comprise an up arrow, a down arrow, and a hyphen bar to indicate up trending/prediction, down trending/prediction, or neutral trending/prediction.

FIG. 11C illustrates an exemplary display screen showing trend graph 1140 including trend line 1142 for HbMet. In an embodiment, the trend line 1142 may be advantageously colored for quick straightforward recognition of the trending parameter, may be associated with any one or more of the foregoing alarm attributes, may include trending lines for

18

other parameters, or the like. The display screen also shows trending directional indicators 1142, 1144 for many of the displayed physiological parameters. In an embodiment, the directional indicators 1142, 1144 may advantageously comprise arrows showing the recent trend, predicted trend, user-customizable trend, combinations thereof, or the like for the associated parameters. In an embodiment, the directional indicators 1142, 1144 comprises an up arrow indicating a rising trend/predicted trend, a middle bar indicating a somewhat stable trend/predicted trend, and a down arrow indicating a lowering trend/predicted trend. An artisan will recognize a wide variety of other directional indicators 1142, 1144 from the disclosure herein.

FIG. 11D shows an exemplary display screen in vertical format. Such vertical format could be user actuated or based on a gravity switch. FIGS. 11E-11F illustrate additional displays of various physiological parameters similar to those discussed in the foregoing. As shown in FIG. 11G, the display includes a measured value of SpO₂ 1162, a measured value of pulse rate 1164 in BPM, a plethysmograph 1166, a HbCO bar 1168, and a HbMet bar 1170. In an embodiment, the HbCO bar 1168 and HbMet bar 1170 may advantageously behave the same or similarly to the HbCO bar 212 and HbMet bar 712. Moreover, similar bars may advantageously display any of the physiological parameters discussed herein using display indicia appropriate to that parameter. For example, a SpO₂ or SpaO₂ bar may advantageously range from about 0% to about 100%, and more preferably range from about 50% to about 100%, while a Hbt bar may advantageously range from about 0 to about 30.

Moreover, similar to the disclosure above, the measured value of SpO₂ 1162 may advantageously toggle to measured values of HbCO, HbMet, Hbt, or the like based on, for example, actuation of user input keys, or the like.

In addition to the foregoing, the display may also include graphical data showing one or more color-coded or other identifying indicia for traces of trend data. Moreover, other graphical presentations may advantageously provide readily identifiable indications of monitored parameters or combinations of monitored parameters of the patient. For example, in an embodiment, the display includes a SpaO₂ graph 1172. The SpaO₂ graph 1172 plots SpO₂ as a function of other blood analytes (1-SpaO₂), where SpaO₂ comprises HbO₂ expressed as a percentage of the four main hemoglobin species, i.e., HbO₂, Hb, HbCO, and HbMet. Thus, as shown in FIG. 11C, as the slope of the displayed line or arrow increases, the caregiver can readily note that the majority of hemoglobin carriers are being used to carry oxygen, and not, for example, harmful carbon monoxide. On the other hand, as the slope decreases, the caregiver can readily and advantageously note that the number of hemoglobin species available to carry oxygen is decreasing, regardless of the current value of SpO₂. Moreover, the length of the arrow or line also provides an indication of wellness, e.g., the higher the line the more oxygen saturation, the lower the line, the more likely there may be desaturation event, or the like.

Thus, the SpaO₂ graph 1172 provides the caregiver with the ability to recognize that even though the measured value of SpO₂ may be within acceptable ranges, there are potentially an unacceptable number of hemoglobin carriers unavailable for carrying oxygen, and that other potential problems may exist, such as, for example, harmful carbon monoxide levels, or the like. In an embodiment, various alarm conditions may cause the graph 1172 to change color, flash, or any combination of alarm indications discussed in the foregoing. Moreover, FIG. 11I illustrates yet an additional display of the foregoing parameters.

An embodiment may also include the monitor **1100** advantageously defining regions of wellness/severity of the monitored patient. For example, because the graph **1172** comprises two dimensions, the monitor **1100** may advantageously define regions where the patient's measured physiological parameters are considered acceptable, regions where the patient is considered at risk, regions where the patient is critical, and the like. For example, one region of acceptability may include a high SpO_2 and a low 1-SpaO_2 , another region of risk may include a high SpO_2 and a high 1-SpaO_2 , and another critical region may include a low SpO_2 and a high 1-SpaO_2 . Moreover, an artisan will recognize from the disclosure herein that different parameters may also be combined to provide readily identifiable indications of patient wellness.

In addition to or as an alternative to the two dimensional SpaO_2 graph **1172**, the monitor **1100** may also include a three dimensional graph, such as, for example, extending the graph **1172** along the variable of time. In this embodiment, the forgoing regions advantageously become three dimensional surfaces of wellness. Moreover, trend data may also be advantageously added to the surface to provide a history of when particular monitored parameters dipped in and out of various surfaces of wellness, risk, criticality, or the like. Such trend data could be color-coded, text identified, or the like. An artisan will also recognize that such surfaces may be dynamic. For example, measurements of HbCO > about 5 may dictate that trend data showing SpO_2 < about 90% should be considered critical; however, measurements of HbCO < about 5 may dictate only SpO_2 < about 85% would be critical. Again, an artisan will recognize from the disclosure herein other parameter combinations to create a wide variety of wellness/critical regions or surfaces that provide readily available visual or audio indications of patient well being, trigger specific alarms, or the like.

Moreover, the monitor **1100** may advantageously employ enlargement or reorganization of parameter data based on, for example, the severity of the measurement. For example, the monitor **1100** may display values for HbCO in a small portion of the screen or in the background, and when HbCO begins to approach abnormal levels, the small portion may advantageously grown as severity increases, even in some embodiments to dominate the display. Such visual alarming can be combined with audio alarms such as announcements, alarms, rising frequencies, or the like, and other visual alarms such as flashing, coloration, or the like to assist a caregiver in noticing the increasing severity of a monitored parameter. In an embodiment, a location of the display of an alarming value is changed to be displayed in a larger display area, such as **1102**, so as to be readily noticeable and its display values readily ascertainable.

Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. For example, the monitor **100** may advantageously be adapted to monitor or be included in a monitor capable of measuring physiological parameters other than those determined through absorption spectroscopy, such as, for example, blood pressure, ECG, EKG, respiratory rates, volumes, inputs for blood pressure sensors, acoustical sensors, and the like. Moreover, the monitor **100** may be adapted for wireless communication to and from the sensor **106**, and/or to and from other monitoring devices, such as, for example, multi-parameter or legacy monitoring devices.

Also, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Accordingly, the present invention is

not intended to be limited by the reaction of the preferred embodiments, but is to be defined by reference to the appended claims.

Additionally, all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

What is claimed is:

1. A method of graphically displaying a plurality of physiological measurements on a single display, the method comprising:

obtaining a first physiological measurement;
obtaining a second physiological measurement;
displaying an indication of the first physiological measurement on a first display area;

displaying an indication of the second physiological measurement on the first display area, wherein the first display area alternates between displaying the indication of the first physiological measurement and the indication of the second physiological measurement;

automatically switching between the indication of the first physiological measurement and the indication of the second physiological measurement without human intervention when a trend of either the first physiological measurement or the second physiological measurement indicate an alarm condition.

2. The method of claim 1, wherein the first physiological measurement is one of carbon monoxide saturation, methemoglobin saturation, total hemoglobin, oxygen saturation, and fractional oxygen saturation.

3. The method of claim 1, wherein the second physiological measurement is one of carbon monoxide saturation, methemoglobin saturation, total hemoglobin, oxygen saturation, and fractional oxygen saturation.

4. The method of claim 1, further comprising switching between the indication of the first physiological measurement and the indication of the second physiological measurement based on a user activated input.

5. The method of claim 1, wherein the indication of the first physiological measurement is an indication of the trend of the first physiological measurement.

6. The method of claim 1, further comprising changing a color of the displayed indication of the physiological measurement based on a severity of the alarm condition.

7. The method of claim 1, further comprising changing a size of the indication of the first physiological measurement based on a severity of the alarm condition.

8. A physiological measurement and display system comprising:

a physiological sensor including a plurality of light emitting elements and a detector, the physiological sensor configured to measure and indication of at least two physiological parameters of a patient;

one or more processors configured to determine at least two physiological parameter measurements using the measured indication from the physiological sensor;

a display, the display including a first display area, at least a portion of each of the at least two physiological parameter measurements are alternatively displayed in the same display area, wherein the physiological parameter displayed switches from a first parameter to a second parameter when a trend of the second parameter indicates a worsening condition of the patient.

9. The system of claim 8, wherein the at least two physiological measurements comprise one or more of carbon mon-

21

oxide saturation, methemoglobin saturation, total hemoglobin, oxygen saturation, and fractional oxygen saturation.

10. The system of claim 8, wherein a color of the displayed physiological parameter measurement is changed based on a severity of the worsening condition of the patient. 5

11. The system of claim 8, wherein a size of the displayed physiological parameter measurement is changed based on a severity of the worsening condition of the patient.

12. A physiological parameter display system capable of receiving and displaying measurements, the system comprising: 10

a display configured to display a plurality of indications of physiological measurements of a patient; and
at least one processor configured to alternate displaying at least two different measurement indications of physiological parameters in the same display area of the display, the at least one processor configured to switch from displaying a first measurement indication to displaying a second measurement indication when the second measurement indication indicates a worsening state of a patient under measurement. 20

13. The system of claim 12, wherein the plurality of indications of physiological measurements of a patient comprise one or more of carbon monoxide saturation, methemoglobin saturation, total hemoglobin, oxygen saturation, and fractional oxygen saturation. 25

14. The system of claim 12, wherein a color of the displayed measurement indication is changed based on a severity of the worsening condition of the patient.

15. The system of claim 12, wherein a size of the displayed measurement indication is changed based on a severity of the worsening condition of the patient. 30

* * * * *

22